sgusers3的部落格

廣東自貿區方案正呼之欲出。南都記者昨日多方求證獲悉，迷你倉新蒲崗目前廣東自貿區的建設方案已經見雛形，為了提高廣東自貿區成功獲批概率，目前由省層面進行統籌，擬定將廣州的南沙、深圳的前海、珠海的橫琴和廣州白雲空港四地“打包”聯建。橫琴相關負責人昨日向南都記者證實，本周內商務部、發改委等部委聯合調研組將到廣東調研申報自貿區工作。不過，前海相關人士則認為，盡管調研工作近期將進行，但國家層面短期再批新的自貿區的概率不大。部委將到粵調研隨著上海自由貿易區的相關政策陸續出台，自貿區就成為各界關注的焦點。近日有消息稱，廣東已確定南沙、前海、橫琴、廣州白雲空港四地聯合申報粵港澳自由貿易區。而昨日商務部網站亦刊登文章來源為“商務部駐深圳特派員辦事處”的相關消息稱，“廣東自由貿易區或許能在明年初獲批的消息近來引發廣泛關注。目前初步方案已經成型，近期將迎來商務部調研組對其進行可行性評估，評估通過後將報送國務院進行審批。”對此消息，商務部深圳特派員辦事處有關工作人員不置可否，僅表示，“商務信息”一般是抓取出來的，來自媒體的信息。而至於新聞由頭來自何處並不清楚。南都記者留意到，下午上述信息已被刪。“目前我們不太清楚進程，自貿區的建設由省進行統籌建設，各區不進行單獨申請。”橫琴管委會一位相關負責人在接受南都記者採訪時表示，廣東的自貿區建設方案由省級層面進行統籌。南沙區宣傳負責人在接受南都記者採訪時也表示，自貿區的有關回應應以省與市的說法為主。不過，前海方面證實了四地打包聯建廣東自貿區的情況。該前海人士在接受南都記者採訪時證實：“廣東省劃下的上報自貿區四個地方是廣州的南沙、深圳的前海、珠海的橫琴和廣州白雲空港，這是一鍋飯。”據悉，目前方案已經基本成型。根據初步方案，廣東版自貿區的定位仍然鎖定粵港澳合作，近期各地將迎來商務部調研組對其可行性進行評估，評估通過後將直接報送國務院進行審批。對此，南都記者從廣東省金融辦相關負責人處獲悉，商務部近期有意到廣州調查自貿區的事，接待部門是廣州市的有關單位。而橫琴相關負責人昨日向也南都記者證實，本周內商務部、發改委等部委聯合調研組將到廣東調研申報自貿區工作。目前橫琴正按照省政府統一部署，積極做好配合準備工作。南都記者從其他渠道獲悉，目前各級政府對前海進展情況也非常關注。深圳市政府相關領導近期和前海局主要領導面談，瞭解前海工作。中央對前海動態也非常關心。近期，新華社已經派專人到前海，深入各部門調研一周左右時間，重點是前海相關工作的具體進展情況等。隨後寫成內參，上報中央。不過，上述人士同時指出，目前調研組還沒有到前海，預計主要調研工作是在省里，調研組留給前海的時間最多僅在半天左右。攜手聯建提高迷你倉出租批率從目前各方的信息看，廣東自貿區方案所涉的南沙、橫琴、前海、廣州白雲空港四地面積相加，已遠超上海已經確定為自貿區的28.78平方公里。其中，南沙新區面積為803平方公里，橫琴新區為106.46平方公里，前海深港現代服務業合作區則約有15平方公里。而廣州方面公佈的廣州空港經濟區總面積約439平方公里。對於廣東採取四地“打包”聯建的自貿區，暨南大學特區港澳經濟研究所所長陳恩在接受南都記者採訪時表示：“這樣獲批的概率更大。”陳恩指出，上海全國性優勢更加突出，其獲得全國首個試點，具有實驗性質。相較而言，廣東的優勢在於粵港澳合作。但是目前來看，區域內的多個新區在功能上互有重疊，形成互相競爭，單獨申請獲批的可能性非常小，而聯手一起申請，根據各地的區位優勢，打粵港澳牌，進行跨境自貿試點，獲批可能非常大。不過，前海相關人士則對廣東自貿區獲批不太樂觀。前海一位相關人士對南都記者坦言：“上海被批准成立自貿區後，短期不會再批准成立新的自貿區。”對於即將進行的調研活動，他認為：“�動自貿區的調研，從工作上是需要的。”該人士分析指出，總體上，國內各地展開跟隨式競爭意義不大。一個地方批了一個特殊區後，全國各地也在後跟風報批，並不可取。因為在上海自貿區成為國家試驗田之前，國家決策層應該是通盤考慮過。“這種實驗，不能濫也不能亂。所以像上海成立自貿區，重點不是獲得多少優惠政策，而是在擴大開放。”以粵港澳合作為特色據悉，南沙、前海、橫琴獲批國家戰略發展平台時定位有所不同，南沙的定位為粵港澳全面合作示範區，橫琴新區的定位為粵港澳緊密合作新載體，而前海則于去年獲批深港現代服務業合作區。對此，陳恩強調，由省政府層面進行統籌，攜手四地打包建自貿區後，上述四區特色應該進一步強化，形成分工互補的格局。他指出，前海面積較小，且鄰近香港，必須主要發展金融業和高端服務業；橫琴則以澳門為依托，產業重點是旅遊和科教；而南沙面積較大，可聚焦重點發展航運、物流、金融等。對此，他特別指出，上述方案需要發揮廣東省層面的整合的作用而前海相關人士也指出了，廣東自貿區應該和香港關稅區有所不同。香港是全球最大自由港，開放優勢非常獨特和明顯。而廣東當務之急是粵港澳服務貿易自由化要率先實現。相較于已經獲批的上海自貿區，陳恩認為，廣東自貿區應該體現粵港澳合作，在粵港澳跨境貿易以及人民幣國際化方面進行突破。前海相關人士則認為，從國家戰略層面上看，上海成立自貿區是國家主動在參與新一代貿易投資規則競爭，搶奪境外貿易投資話語權、制定權的定位，因此，上海自貿區主要聚焦貿易投資領域擴大和對外開放，而前海整體是金融領域對外開放的實驗示範窗口。南都記者 陳穎 梁小嬋 梁永建迷你倉

2011年11月，迷你倉最平 我國第一個擁有完全自主知識產權自升式鑽井平台CP-300下水。張允強攝遼寧正一步步向廣闊的大海發展。自2005年“轉身向海”，遼寧以前所未有的魄力開發開放身後2200多公里長的海岸線。2009年，遼寧沿海經濟帶開發開放上升為國家戰略，不斷加大的開發力度，讓遼寧的沿海地帶成為我國經濟發展速度最快的區域之一。如今，當一條佈滿新興產業和現代都市的黃金地帶日漸清晰之時，這裡又成為我國東北地區對外開放的重要平台。昔日粗放的老工業基地不斷被嶄新的高新產業平台所取代，經濟結構不斷優化，經濟發展的質量和效益合理提升，就業和收入、環境保護和資源節約等方面正呈現出新的提升態勢。新興產業——引領老工業基地轉型升級儀器儀表一直是丹東的特色產業，隨著遼寧沿海經濟帶開發開放力度不斷加大，丹東的儀器儀表產業就如同儀表盤上的指針一樣，飛速地運轉著。自2009年4月建設遼寧儀器儀表產業基地，如今丹東已經形成工業自動化儀表與控制系統、醫療儀器、科學儀器、分析檢測儀器、電子與電工測量、各類專用儀器和儀表元器件等六大主要門類齊全的特色產業基地。2012年，這個位於鴨綠江出海口的產業基地主營業務收入輕鬆超過100億元，朝著1000億元的目標邁進。產值超 1000 億元的特色產業集群，如今在遼寧沿海經濟帶並不罕見。2012 年，大連軟件和信息技術服務產業集群銷售收入突破1000億元大關，一批新興的軟件產業在這裡強勢崛起。網絡產業持續高速發展，博濤多媒體“移動式球幕飛行影院”被列入科技部2013年重點科技支撐項目，國內著名遊戲公司人人遊戲和日本第一大手機運營平台公司DENA同時入駐，手機遊戲、網頁遊戲多元化發展，推動動漫遊戲產業快速發展。與此同時，產業的高端化發展趨勢明顯，貝斯特電子、陸海科技、海大航科等公司研發的船舶軟件，樓蘭科技、�明海通等公司的汽車導航軟件，以及大連華信的海洋智能牧場等一批軟件產品正快速被市場接納。“高、新、快、優”成為大連軟件業的代名詞。產業，特別是推動結構調整的新興產業的快速發展，得益于優惠政策的助力。自開�沿海開發大幕，到遼寧沿海經濟帶開發開放上升為國家戰略，遼寧沿海各地的產業發展得到中央和遼寧省的多項政策支持，隨著時間的推移，政策優勢不斷轉 化為產業優勢——對沿海重點園區產業項目每年安排3億元貼息資金，對產業集群公共研發和公共檢測平台項目按有效投資額三分之一給予補助；對新增固定資產投資額10億元以上農產品深加工項目“投十補一”；對服務業聚集區項目貸款給予貼息；對並購海外科技型企業的項目，按並購金額20%給予補助；對沿海重點園區基礎設施建設給予38億元補助。到2012年底，遼寧沿海6市擁有42 個重點工業產業集群，當年銷售收入達到10000多億元。新興產業的壯大是經濟轉型的標誌之一，像丹東儀器儀表、大連軟件和信息技術服務產業等新興產業如今遍佈遼寧沿海經濟帶。隨著英特爾的落戶，大連金州新區的電子信息產業開始叫響全世界。目前金州新區電子信息產業集群已形成以半導體晶圓、LED芯片及外延片等為核心產品門類，現有電子信息產品製造企業471家，其中規模以上企業達109家。英特爾芯片項目于2010年10月正式投產，環宇陽光集團研製的高性能寬帶信息網建設、高可信網絡運營管理平台和高性能匯聚路由器等成套技術設備成為新一代新技術的亮點。2012年，金州新區電子信息產業實現銷售收入592億元，同比增長12.2%。“十二五”期間，這裡的產值也將形成千億級。而在金州新區，將成為千億產業集群的還有裝備製造和石油化工，目前這兩者的產值均達到750億元以上。按照“集群發展、持續創新、行業領先、產品高端”的發展理念，金州新區正不斷把這些更具現代化的新興產業做大做強。新興產業在遼寧沿海經濟帶不斷快速發展壯大，並不斷提高其在產業集群中的比重。大連市已經提出，力爭到“十二五”末，新興產業集群銷售收入占全市產業集群銷售收入的比重達到40%以上。並提出要在電子信息、軟件、工業設計研發、裝備製造、新材料等產業集群發展上取得實質性突破。2012年，遼寧沿海6市經濟總量占全省比重51%，占東北三省25%，遼寧沿海經濟帶不僅是遼寧經濟實現升級的動力，更成為東北腹地經濟轉型的引擎。創新驅動——催生經濟升級強大助推力創新對於在營口安家立戶的卓異科技集團公司來說，就是企業發展的命脈。日前，這家公司一次推出包括礦用應急救援車、防爆指揮車、隔絕式壓縮氧自救器、多參數環境監測儀等9種國內尖端礦難救援設備，並在全國首推“大救援體系”，為井下作業和礦難救援，提供系統全面的解決方案。多年來潛心于礦山安全領域高技術裝備創新研發的卓異科技公司，自從落戶營口，一步步發展成為我國安全應急救援領域的領軍企業，其自主與合作研發的許多高技術產品，填補了國內空白。在地處渤海灣畔的營口，創新是這裡成為推動產業升級的利器。堅持把企業作為自主創新的主體，把科技創新作為調結 構的中心環節，營口在遼寧沿海經濟帶開 發開放進程中不斷引導人才、資本、技術等創新要素向企業集聚。目前，營口擁有企業技術中心113戶，其中，國家級技術中心1戶、省級技術中心41戶。今年上半年，營口市高新技術產品增加值增長27.4%，是規模以上工業增加值的兩倍多。重視創新，營口始終堅持用高新技術改造提升傳統產業，營口市已經制定了全社會研發投入、研發人員數量、授權發明專利、高新技術產品增加值到2017年翻一番的目標，屆時營口高新技術產品增加值占地區生產總值比重將達20%以上，科技進步對經濟增長比重貢獻率將達到60%以上。目前，營口已經初步形成以鎂質材料、精細化工、數控機床、輕印刷設備等產品為主的高新技術產品群，一個個備受市場青睞的產品迅速搶佔國內外市場。2012年，營口高新技術產品增加值達251 億元，較上年增長35%。與營口隔江相望，地處遼河北岸的盤錦是典型的資源型老工業基地，石油一直是這裡發展的命脈。面對日益枯竭的石油資源，盤錦以前所未有的創新精神和舉措，推出海洋工程裝備設計製造技術、塑料新材料工藝技術、高性能合成橡膠工藝技術、大河蟹培育養殖技術等科技創新工程，並帶來一個個前景無限的接續產業。創新驅動如今已令石化及精細化工產業成為千億元產業集群，石油天然氣裝備製造基地也成功躋身國家級新型工業化產業示範基地行列。盤錦從此不再“一油獨大”。2011年11月，由遼寧陸海石油裝備研究院有限公司與遼河石油裝備製造總公司共同設計，遼河石油裝備製造總公司建造的中國第一台具有完全自主知識產權的CP-300自升式鑽井平台在盤錦遼 東灣新區正式下水。CP-300自升式鑽井平台是國內第一個自主完成基本設計、詳細設計、生產設計、工藝技術研究的桁架腿自升式鑽井平台，國產化率達 90%以上。這台鑽井平台的研製成功，標誌著國產自升式鑽井平台邁上新台階，而盤錦裝備製造業在我國海工製造領域的位置因此更加重要。如今在盤錦，齊心協力大幅度提升科技創新對經濟增長的貢獻率，加速實現創 新驅動經濟轉型升級，已成共識。以創新驅動轉型升級，是目前遼寧沿海經濟帶一個個產業園區實現又好又快發展的有效措施。迷你倉新，將在遼寧沿海經濟帶釋放更強大的發展動力。遼寧省已經提出，要切實把科技創新擺在優先發展地位，充分發揮科技創新在加快轉變經濟發展方式中的重要作用，不斷加大科技投入力度，加快運用高新技術和先進適用技術改造傳統產業，著力突破一批關鍵和核心技術，推動科學研究、技術創新、產業發展有效結合，走創新、跨越、融合和可持續的科技發展之路。抓住科技與經濟緊密結合這個核心問題，不斷深化科技體制改革，強化協同創新，提高整體功能，加強統籌協調，整合科技資源，建立基礎研究、應用研究、技術創新和成果轉化協調發展的體制機制。緊緊依靠科技進步，依靠提高勞動者素質，加快形成少投入、多產出、少排放、多利用的生產方式和消費模式，促進遼寧經濟走上內生增長軌道。生態建設——黃金地帶更是綠色地帶斑海豹寧寧作為吉祥物，是正在遼寧舉行的第十二屆全國運動會的關注熱點之一。選擇國家二級保護動物斑海豹作為十二運的吉祥物，彰顯遼寧對沿海經濟帶生態保護的重視態度。幾年前，遼寧修建沿海公路時，為了保護遼東灣斑海豹的核心棲息地——遼寧雙台河口國家級自然保護區，專門將工程規劃路線上移了7公里，為斑海豹留出生存空間。從丹東鴨綠江口濕地到大連蛇島老鐵山，從營口玉石嶺到盤錦雙台河口，錦州醫巫閭山到葫蘆島虹螺山，遍佈13處國家和省級自然保護區的遼寧沿海經濟帶，是條名副其實的生態帶。建設遼寧沿海經濟帶的同時，更要保留這裡的原生態。長度近3000公里的遼寧沿海公路，在串起一座座沿海新城和產業園區的同時，更讓行進在這條遼寧沿海經濟發展大動脈上的人們看到一個個保存完好的生態帶。《遼寧沿海經濟帶發展規劃》明確指出，必須加強生態建設和環境保護，加強28處生態功能區的保護與管理，對遼東灣和鴨綠江口濕地等13處國家和省級自然保護區實行生態環境分區管理。今年，《遼寧海岸帶保護和利用規劃》在遼寧出台，這個我國首個有關海岸帶保護和利用的規劃，是對《遼寧沿海經濟帶發展規劃》的深化和落實，標誌著遼寧沿海經濟帶從以開發為主邁向開發和保護並重的新階段。《規劃》將遼寧沿海經濟帶國土空間劃分為重點保護功能區和重點建設功能區，以資源環境承載能力為基礎，實施功能分類管制；確定不同板塊和岸線的功能定位，規範開發秩序。《規劃》明確在生態功能與開發建設功能出現衝突時，優先保障綠色生態空間的需要；嚴格保護生態、農業漁業和旅遊休閒功能板塊；控制國土開發的規模和強度，確保海岸帶資源可持續利用。按照 《遼寧海岸帶保護和利用規劃》，遼寧海岸帶陸域保護和利用的比例為86:14，海域保護和利用的比例為88: 12，岸線保護和利用的比例為79:21，依據劃定的功能區，進行海岸帶資源開發、生態保護、港口建設、產業和城鎮布局。海岸帶規劃的出台使沿海開發更加科學和理性。地處渤海灣北部的葫蘆島位於遼寧沿海經濟帶的最西邊，有著豐富的濕地資源，濕地總面積33.94萬公頃，其中濱海濕地 19.41 萬公頃，占總濕地面積的57.2%。在該市的濕地中，生物資源極為豐富，有 400余種以鳥類為優勢種的陸生脊椎動物，每年都有近百萬只鳥類在葫蘆島的濕地中棲息停歇，包括60余種國家重點保護的珍稀鳥類。葫蘆島專門出台《葫蘆島市濕地保護管理辦法》，嚴令禁止擅自排放濕地蓄水，禁止向濕地內排放汙水、傾倒固體廢棄物或者投放可能危害水體、水生生物的化學物品等有毒有害物質等規定，就是為保護好這裡的濕地資源。一條環境優美的生態帶，帶來了藍天白雲、清新空氣，讓沿海經濟帶上的座座都市，成為東北腹地乃至全國各地的居民前來旅遊安居的目的地。遼寧的海濱也開始成為國內外旅遊新亮點。今夏的高溫，令四處尋覓避暑勝地的國內外遊客將目光投向遼寧沿海經濟帶。陽光、沙灘、美景，讓來這裡度夏的人們流連忘返。來自大連交通部門的統計顯 示，今夏的旅遊熱，讓大連成為國內客流量最大的地區之一。大連火車站暑運62天共發送旅客 325 萬人次，完成運輸收入46235 萬元，其中最多一天完成 936 萬元。而大連港客運總公司共接送旅客84.3 萬人次，滾裝車輛6.5萬輛。推動遼寧經濟轉型升級，將是今後一段時期的重要工作。隨著遼寧沿海經濟帶開發開放不斷加快，老工業基地全面振興指日可待。文/張允強 蘇大鵬向大海尋求更大發展空間向大海尋找更大發展空間。為實現全面振興，遼寧自 2005 年轉身向海，以“五點一線”建設作為沿海開發的金鑰匙，迅速打開沿海開發開放新局面。昔日荒蕪的廢棄鹽田、鹽堿地、荒灘漸漸變成一條黃金地帶，新產業、都市帶迅速崛起，沿海經濟布局進一步完善，提升了我國在東北亞地區的國際競爭力。遍佈海岸線上的產業園區里， 比比皆是的新興產業， 標誌著產業正由粗放向集約邁進。以軟件業等為代表的高新產業日新月異， 引領產業由低競爭力向高端轉型。產業帶連起城市帶， 一座座現代化新城為產業發展提供著優質服務。旅遊帶的興旺， 為遼寧沿海經濟帶帶來�多關注目光和經濟增長點。隨著產業帶、 城市帶、 旅遊帶的興起， 遼寧沿海經濟帶建設成效明顯。2012年， 遼寧沿海 6 市經濟總量首次超過全省經濟總量的50%。遼寧沿海經濟帶成為推動遼寧老工業基地改革振興的主力。前所未有的崛起速度， 讓遼寧沿海經濟帶邁 出建設步伐的同時， 也為遼寧打造老工業基地經濟升級版不斷拓展著空間。2200多公里長的海岸線上， 一個推動遼寧老工業基地乃至整個東北腹地經濟升級的平台日漸清晰。向海發展， 依托遼寧沿海經濟帶推進老工業基地全面振興， 努力打造遼寧乃至整個東北地區經濟 “升級版”， 遼寧沿海經濟帶是最佳平台。國內外實踐表明， 隨著生產力的發展， 沿海已成為生產力布局的重點地區。目前， 全世界約四分之三的大城市、 工業資本和人口都集中在沿海地帶， 我國 11 個沿海地區國內生產總值占全國60%以上。作為東北地區惟一的沿海地帶， 遼寧沿海經濟帶的崛起， 使整個東北地區對外開放程度得到提升。在破解一系列體制機制難題的同時， 遼寧沿海經濟帶持續釋放發展活力， 整合區域資源， 調 整產業結構， 創造升級空間。在促進老工業基地技術、 人才、 產品、 經營管理新陳代謝的同時， 遼 寧沿海經濟帶還不斷帶動腹地經濟聯動發展， 吸引生產要素集聚， 成為推動遼寧乃至整個東北經濟轉型的重要平台。遼寧沿海經濟帶是我國環渤海地區的重要地帶， 在國家政策激勵下， 在國際國內的產業轉移中， 大量的生產要素在此集聚， 使得遼寧沿海經濟帶成功打造出世界級產業製造帶。隨著建設步伐加快， 遼寧沿海經濟帶已經形成相當實力的產業體系， 科技人才密集， 沿海40 多個園區發展日新月異， 千億元產業集群不斷湧現， 這都為實現工業結構優化升級， 發展先進製造業， 打造高端現代產業體系提供著平台和載體。與此同時， 遼寧沿海經濟帶上建成的高鐵帶、高速公路帶、 機場帶、 港口帶， 也在不斷盤活遼寧全省乃至整個東北腹地經濟發展全局。2012年， 遼寧沿海經濟帶地區生產總值占東北三省25%。合理開發， 有效利用好遼寧沿海經濟帶， 推動遼寧乃至整個東北打造 “升級版” 老工業基地， 是擺在遼寧及其身後100萬平方公里大東北的重要課題。文/蘇大鵬儲存

最近潮流品牌adidas Originals舉行了全港首個3D 打印展覽「WePrint Originals 3D 重塑經典展覽」，自存倉不少人都對「打印」出來的Eason、達明一派嘖嘖稱奇。其實原理是怎樣呢？對一般人又有什麼用途呢？《e 潮》統籌一鋒就嘗試「被打印」，原來只要乖乖擺好甫士10 分鐘就可以，不過工作人員在背後花的工夫可不少！ 統籌：一鋒文：Gary 圖：陳淑安 一鋒Figure 一鋒擺10 分鐘甫士，加上約10 小時的3D 打印， 15cm 高的「一鋒Figure」便完成了！ 效果睇真� A 樣貌：相似度有七成以上，但衣服花紋嫌不夠清晰，相信是由於製作時間不足。 B 配件：衣服上的凹凸紋和光暗位亦算像真，但手表面上的凹位就失蹤了。 C 細位：藏於褲後袋的PassionTeens 漫畫雜誌，連封面人物和書名都清晰可辨，非常滿意。 一鋒評語﹕比想像更快更似「以Artec Eva 採集數據時，好像畀人用熨斗對�，有點搞笑；到工作人員拿出Kinect時更嚇了我一跳，因為沒有想過會用這東西。不過，過程比想像中快，效果亦相當滿意，3D 打印相當細緻，像真度比想像中高！」 立體掃描器收集立體數據 簡單來說，3D 打印是將粉末狀的金屬或塑料等可黏合材料，逐層堆疊來「打印」物體，是一項快速成形技術；在上世紀八十年代開始出現，九十年代成熟及應用在工業層面，如珠寶、鞋和建築設計，近年應用範圍愈來愈廣泛，例如在醫療上可做人工關節、人造骨骼或假牙，甚至有研究可應用於復修文物和犯罪證據。隨�近年成本漸降，更多機構加入開發不同產品。 3D 打印可以分兩個主要部分：製作圖像及打印。前者來說，現時3D 繪圖軟件已發展得相當成熟，能製作不同產品或零件的3D 圖像，過程不算困難；較複雜的是如何收集立體影像的數據，尤其是特定的物件如人體、古蹟等。 要取得物件或環境的立體影像數據，須使用不同的立體掃描器，甚至是多台配合操作。例如在今次的3D 打印展覽中，一眾藝人的立體數據，主要是利用一台外形似熨斗、名為Artec Eva 的掃描儀（圖1），它每秒可拍攝16 張相片及採集200萬點數據，並自動校準及對齊， 化成立體數據。在5 至10 分鐘的掃描過程中，藝人需維持同一動作，而工作人員拿起Artec Eva 圍繞對象，上上下下的不斷掃描；較精細的部分如頭髮， 則需以Xbox 的Kinect 鏡頭，配合Artec的軟件去收集數據。 至於展覽中，全球最後一輛「大白鯊」長版兩輪巴士的3D 打印模型，則是利用Faro Focus 3D 掃描器（圖2），配合Artec Eva 收集數據。Focus 3D 採用激光技術，每秒能收集97.6 萬點數據，掃描距離由0.6m 至120m，只需數分鐘即可繪出複雜環境和幾何結構的詳細3D 圖像。它因而獲選用來採集多個世界古蹟及文化遺產的立體數據，包括悉尼歌劇院、美國總統山、中國清東陵等。 主辦人：重塑集體回憶 曾辦「多啦A 夢�啦！誕生前100 年祭」及「黃色巨鴨」展的AllRightsReserved Ltd，正是今次展覽的創意策劃。負責人SK 表示，希望利用科技去記錄及展現香港的集體回憶，結果花了兩個多月，就籌辦了是次展覽。「Artec Eva 已經買來一段時間，一部約10多萬港元（包括程式），用來學習處理立體圖像數據，但就未試過3D 打印。」SK 說， 「後來巧合認識JIE Technology，他們一直為客戶處理3D 打印，可以替我們打印3D 模型；之後與adidas 談起用科技記錄及展現香港集體回憶的概念，結果一拍即合，還請來另一3D 打印公司PRECISE 合作」。 SK 認為今次最難得的，就是為「大白鯊」巴士留下紀錄， 「因為已經是最後一輛了，不知何時會消失。立體掃描的好處，是可以將快要消失的東西記錄下來，並透過3D 打印重塑出來」。 層層疊黏貼3D 成品 收集影像數據後，未必能立即開始打印。SK 解釋由於從不同掃描器採集的數據，格式未必相同，須先用軟件將之統一、整合，才能取得完整、可以使用的立體影像數據，這部分其實最花時間，每組數據需時差不多要20 小時以上， 「之前日本亦有類似的立體掃描和打印活動，但負責人輕視了處理影像數據的難度，結果比原定時間遲了很多才能打印出來」。另外，掃描對象若屬懸空的物件，例如眼鏡和羊咩迷你倉新蒲崗，原來掃描器也辨認不到，掃描後會好像「畫」在面上，需要分開處理。 有了完整的立體影像數據，就可以打印。現時多個品牌都推出3D 打印機，以商用和工業用為主，亦有民用的。打印的方式主要是「累積技術」，即透過讀取立體數據的切面信息，用液體狀、粉狀或片狀的材料，將這些切面逐層打印出來，再將各層黏合以形成實體。 不過，不同開發商的技術各有不同，採用物料亦有分別，較常見的有石膏、ABS 樹脂、聚乳酸、合金、熱塑性膠料，有些甚至可使用食材如朱古力漿。各款打印方式的需時和成本皆不同，也各有優劣，例如石膏打印的成本較低但易碎；ABS 樹脂較堅固，適合大型的打印品，但色彩有限制。 未來趨勢：不買東西自己印 「相信3D 打印將愈見流行，到時很多東西大家都不用出外買，而是自己印。」SK 說： 「舉個例，眼鏡螺絲鬆脫遺失了，大家只要上網付幾塊錢，買個螺絲的立體影像檔案，就可以自己打印一口，不用再大費周章到處找。」 e 同級 全球最大掃描器3 秒掃勻全身 在會場中，只要捐款$50 就可以一試立體掃描。如果以ArtecEva 作掃描器， 豈非要大排長龍？原來會場設立另一組立體掃描儀器TIM（This Is Me），只需3 秒，就可以360 度掃描人體外形，是暫時市面最大的立體掃描器。 TIM 是由基地在迪拜的PRECISE 公司研發，由4 組器材組成，每組均有兩部數碼相機、一部投影機及一台電腦，分別置於一個4×4m 房間的四角。掃描時，由相機記錄影像，投影機則投射出不同形狀的信號，方便電腦將影像整合成數據，工作人員只需以ZBrush 等立體繪圖軟件略作修改便可使用。 PRECISE 的主要業務是生產立體雕刻， 主席LotharHohmann 表示，TIM 可以快速掃描立體影像，特別適合用於會移動的物品如人、動物。由於影像準繩度高，編輯亦相對容易。他又說： 「3D 打印肯定會愈來愈流行，也愈趨便宜，但會否普及到每人家中都有一台3D 打印機呢？那就視乎有什麼內容可以打印，現在看來，還是光顧打印專門店比較合適。」 購物或捐款玩3D 打印 We Print Originals 3D 重塑經典展覽日期：即日至9 月18 日地點：尖沙嘴漢口道adidas 旗艦店 買滿$3800 送藍色小人偶在六家指定adidas 購物滿$3800（最多3 張有效單據），即可到展覽場地，由專人來立體掃描。約兩三星期後，就可以得到一個專屬約6cm 高的藍色3D 人偶。 鬥快捐錢儲like 賞彩色大公仔只要在展覽場地捐$50 予願望成真基金，可體驗立體掃描，以及獲得adidas Originals $50 現金券，每日名額100 個；若將立體掃描相片公開至facebook 或instagram，獲得滿500 個「讚好」，並將資料電郵至adidashk_originals@adidas.com（詳情請留意主辦單位的宣傳單張），更有機會獲贈3D 打印的20cm 專屬彩色肖像人偶。活動分兩階段，第一階段於本周四晚上11:59 截止，第二階段為9 月13 日至18 日。每階段名額只得3 個，先到先得。 查詢：.facebook.com/adidasoriginals 「被」掃描三部曲1. 工作人員先用Artec Eva 圍�一鋒掃描，過程約5 分鐘。2. 較精細的地方如頭髮，則以Kinect鏡頭採集數據，約需5 分鐘。3. 將採集的資料整合及處理成完整數據，便可開始列印。 潮玩回憶以3D 打印做出Twins 及舊款的紅色皇冠郵筒的塑像，潮玩集體回憶。 兩倍大Eason展覽負責人SK 與200%Eason 模型。他稱臉容放大後會「走樣」，最好的效果還是1:1 打印。 主席與TIMLothar Hohmann 與他肩上的3D立體打印人偶合照，背後是立體掃描儀器TIM。 掃描信號掃描時，投影機投射出不同形狀的信號，方便電腦將四組影像整合。 效果細緻 以3D 打印出來的「大白鯊」長版兩輪巴士模型，可以做到中空的效果，欄杆、扶手、水撥的效果亦相當仔細。 成本一萬 展覽中眾藝人的30cm 高3D 人偶，是以石膏加彩色物料打印， 成本接近一萬元。 禮盒收藏藍色人偶收藏於經典鞋盒禮品套裝內。 立體掃描相片所有捐款者將可獲得一張立體掃描相片，想擁有20cm高的彩色人偶，就要盡快擺上網儲Like！迷你倉出租

Source: Bangkok Post, ThailandSept.文件倉 10--Thailand's property market will likely see flat growth over the next 18 months in line with the slowing economy and consumer spending, says property developers and economic experts.The Thai economy in the second half of this year may expand by only 3.5% compared with 11.1% in the same period last year, which is considered an anomaly, Somphob Manarungsan, rector of the Panyapiwat Institute of Management, told a CP Group seminar yesterday."Last year's second-half growth will be hard to match, as it was 'on steroids', supercharged by populist policies," he said. "We should therefore aim at maintaining economic stability rather than accelerate growth given the spate of uncertainties, be it external and internal."He said external uncertainties include the US winding down its bond-buying scheme this year and an economic paradox in which developed countries such as the US and Japan face deflation while developing economies such as India and Indonesia feel inflationary pressure. A possible US-led military strike on Syria may also push up fuel prices, adding to the costs of doing businesses, said Mr Somphob.On top of that, Thailand is suffering a double blow of political and economic uncertainty at home.Sunthorn Arunanondchai, vice-chairman of the CP Group and chief executive of CP Land Co, said Thailand's GDP is estimated to grow by 4.1% this year provided there are no more negative factors. However, fuel prices may shoot up on the military strike on Syria."The property sector is unlikely to weigh on the economy or cause a bubble, as it is very difficult for developers to ask存倉for project loans these days," he said.Prasert Taedullayasatit, managing director of the SET-listed developer Pruksa Real Estate Plc (PS), also said at a press conference yesterday that consumers are increasingly concerned about a slowdown after second-quarter growth of only 2.8%."The property market may see flat growth, and condominiums will increasingly dominate the housing sector, making up 60% of total market value from 55% last year. Developer must adjust their portfolios to keep up with this trend," he said.PS recorded 14 billion baht in first-half condo sales, double its target, from six new projects. It also booked 3 billion baht in condo revenue during the period.As of Aug 31, it had a condo sales backlog of 24 billion baht, of which 5 billion will be realised this year.Thailand's housing market is projected to be worth 335 billion baht, of which 193 billion baht or 57.6% will be condos.PS claims to command the largest market share in Greater Bangkok's condominium market at 9% in the first half, up from 4% last year."We won't build condos upcountry this year, as the market is fragmented, small and unsustainable," said Mr Prasert. "Demand in the provinces is also limited."PS will launch The Reserve, a new condo project worth 1.8 billion baht on Sept 22. Located on a 3.5-rai plot on Soi Kasemsant 3 near National Stadium skytrain station, it will comprise 273 units sized from 27-87 square metres and priced at 160,000 baht per sq m.Copyright: ___ (c)2013 the Bangkok Post (Bangkok, Thailand) Visit the Bangkok Post (Bangkok, Thailand) at .bangkokpost.com Distributed by MCT Information Services迷你倉

By ZHENG JINRAN zhengjinran@chinadaily.self storagecom.c County bene? ts from transport and trade in commoditiesBuilding on its solid eco- nomic foundation and a series of new projects, local oi cials in Zhengding county of Shi- jiazhuang, Hebei province are expecting a continued surge in the economy.“Construction of an indus- trial park and a new district will surely further boost the coun- ty’s long-term development,”said oi cials.Shijiazhuang Airport Indus- trial Park covers 124 square kilometers and is served by a transport network that includes the city’s airport, an expressway, a high-speed railway and an urban light rail connection.Adjacent to the Shijiazhuang Zhengding International Air- port, the park is 30 kilometers from the city, 200 km from Bei- jing, 350 km from Tianjin New Port and 300 km from Huang- hua Port.It focuses on air transport, maintenance, aviation indus-tries and high-end services. To attract investment, the local government has designed a series of preferential policies and built a bonded zone inside the park.Along with construction of the airport industrial park, Zhengding New District is also moving forward.It will integrate the old city of Shijiazhuang with Zhengding to improve the urban layout and provide larger develop- ment space for both areas.Zhengding has been a busi- ness center for centuries due to its location on the trai c routes in northern China.In 2012, its GDP totaled 22.5 billion yuan ($3.68 billion), an increase of 9 percent.h e i gure reached 10.6 bil- lion yuan in the i rst half of this year, up 9 percent compared to the same period last year, mak- ing it an economic heavyweight among all counties in the prov- ince.The county’s per capita income for urban residents hit 13,700 yuan last year, also an increase of 9 percent.For seven consecutive years, the annual Green Book on small and medium-sized cities from the Chinese Academy of Social Sciences has listed Zhengding as one of the top 100 cities with the greatest investment poten- tial.Its plan is sustainable devel- opment, said local oi cials.“The Zhengding govern- ment will make ef orts in both agriculture and secondary industries to fuel overall devel- opment,” they said.As a commerce center in northern China, Zhengding has many natural advantages that have been augmented by projects to promote trade and investment. It now has many industrial parks including those for services and logistics.And the local market is also fueled by its booming small- commodities trade.The county has hosted six annual international trade fairs since 2008, including the 2013 China Shijiazhuang (Zheng- ding) International Commodi- ties Fair in April.The fair attracted foreign companies from Southeast Asia, South America, East- ern Europe and Taiwan. Big brands from home and abroad accounted for 40 percent of the 1,500 booths this year.Xu Xiuran, Cheng Yuhong and Wu Jun contributed to this story.Betters amenities, environment raise the quality of life By ZHENG JINRAN zhengjinran@chinadaily.com.cn h e local government of Zhengding said it will make big strides in environmental protec- tion in the near future.“Our goal is to make the county one of the most livable places in China, and we have already issued a new urban plan to improve the road network, infrastructure and other aspects,” said oi cials.h e local government has spent more than 80 million yuan ($13.11 billion) on four major roads and bus routes that extend to Shijia- zhuang, capital of He迷你倉ei.Another 40 million yuan has gone into nature conservation projects.The government also plans to increase spending on social welfare, especially for resi- dents in rural areas.It has invested more than 94 million yuan to upgrade 47 village roads and another 435 million yuan in 25 social welfare programs including public housing, employment, educa- tion and medical care.It is also striving to build more recreationalfacilities for residents. It has developed large green spaces in the city area including Chang- shan Park that opened in September 2012.Oi cial statistics show the green coverage of urban area has reached 37 percent and 43 percent for the entire county, respectively.To curb the worsening air and water quality, the county government has adopted a series of measures to conserve energy and reduce emis- sions. In 2012, the government met its targets as the county had 323 good air quality days and chemical oxygen demand in rivers was lowered to 97.6mg/L.h e energy intensity per unit of GDP was reduced by 3.8 percent for the year.Xu Xiuran, Cheng Yuhong and Wu Jun contributed to this story.‘Splendid history’ fuels tourism trade By ZHENG JINRAN zhengjinran@chinadaily.com.cn With a rich diversity of his- torical sites as one of the promi- nent ancient towns in northern China, Zhengding’s tourism industry is expected to con- tinue to fuel the local economy, said local oi cials.Founded in 770 BC as Xianyu, its name was changed to Zhengding in 1723 during the Qing Dynasty.Along with Beijing and Baoding, it was one of the most important political, military, economic and cultural centers of northern China for 1,500 years, “The splendid history is a name card for Zhengding, which requires the county to protect the ancient buildings and boost traditional culture,”said local oi cials.“The long history has left numerous cultural relics and historic sites.”Among them are 38 build- ings dating back to the Sui (AD 581-618) and Tang (AD 618- 907) dynasties. Nine historical heritage sites are under national protection and another five have provincial protection.Most of them are Buddhist rel- ics.Zhengding has been a vital religious center for more than 1,400 years.It is home to several major schools of Zen Buddhism.One of its major temples is Longxing Monastery whose buildings have been preserved almost intact. It is home to a world-renowned bronze statue of Bodhisattva Guanyin, or Avalokitesvara.The bell tower standing at Kaiyuan Temple is the only one from the Tang Dynasty still standing.Four famous pagodas, each with its own architectural style, are must-see destinations for tourists.Pieces of glazed pottery excavated from the remnants of a Yangshao culture site dat- ing back to 7,000 years ago are the oldest known porcelain in the world. The rich cultural heritage earns the county the title as “great treasure house of Chinese ancient buildings”,said local oi cials.Zhengding was also the home of historical figures Zhao Yun, a famous general in the h ree Kingdoms Peri- od (AD 220-280), and Fan Zhongyan, one of the greatest Confucian scholars in all of ancient China, who lived dur- ing the Song Dynasty (960- 1279). Zhengding was a center of Yuan Opera in the heyday of the Yuan Dynasty (1271- 1368).“h e local government has issued a series of measures to restore the damaged build- ings in a bid to preserve the county as a famous culture center in China,” said oi cials.Xu Xiuran, Cheng Yuhong and Wu Jun contributed to this story.文件倉

IN THE face of Australia's new government, little will change the status quo for SingTel's Optus for now, industry watchers say.自存倉While analysts are keeping one eye on the Australian dollar and the other on the country's National Broadband Network (NBN) post-election, the former is at the mercy of China and the latter will have a limited impact on Optus.Last month, SingTel was forced to revise its revenue guidance downwards for the rest of the financial year ending March 2014 after the Australian dollar took a tumble. Optus, its Australian subsidiary, accounts for about 60 per cent of the SingTel group's revenue. Then, the forward exchange rate that the telco had used was S$1.1622 to the Australian dollar.The exchange rate steadied over the weekend to hover just above S$1.17 and 92 US cents - up from 89 US cents a week ago. Even so, this was driven less by the Liberal-National coalition victory and more by better trade data coming out of the Chinese economy, for which the Australian dollar is seen as a proxy.On Sunday, Chinese data showed that exports were up 7.2 per cent in August, beating expectations of a 6 per cent increase. Even so, the consensus on a slowdown in China's growth for the medium term remains unchanged.While new prime minister Tony Abbott has pledged to axe the carbon tax in a move that could boost the Australian dollar, it will take a lot to compel greater optimism in SingTel, given how the forward exchange rate had deteriorated by 1,133 pips when the telco downgraded its outlook.At the same time, the new government could reshape Australia's largest infrastructure project, the NBN. Mr Abbott has publicly taken a narrow view of how much money and time the NBN project requires, and has proposed a cheaper, scaled-back version that could see the network mostly rolled out by 2019 inst迷你倉新蒲崗ad of 2021.Optus, for the most part, has been supportive of the NBN which it believes will level the playing field for fixed services, and will have marginal reason to cheer a faster rollout.Even so, analysts believe that a speedier network rollout will not be a primary factor in altering the dominance of Optus's rival, Telstra, in the broadband stakes."There'll be a slight boost, but it depends on how much of a foothold (Optus) can get. At the moment, their market share is not very high. Telstra still has the bulk of it, and competition is quite tough there in terms of broadband," said OCBC Investment Research's Carey Wong.Currently, Telstra has more reason to feel trepidation, as the telco faces a renegotiation of an A$11-billion NBN agreement signed with the old government. At the same time, however, a need for a faster network rollout creates a dependence on Telstra's expertise, which it will leverage to its advantage.As these issues coalesce, there are other things that must preoccupy Optus more than the NBN does. The mobile market, which makes up the bulk of its revenue, is experiencing fierce competition from both Telstra and Vodafone. In response, Optus has pared headcount by at least 10 per cent from a year ago and cut its retail distribution footprint by 40 per cent.For now, the cost-cutting is paying off. While revenue for the last reported quarter was 5.3 per cent lower at A$2.12 billion, underlying net profit grew 3.6 per cent to A$167 million.Once the fat has been trimmed, however, the telco will have to focus on revenue growth in a newly glum economy, hampered by uncertainty over government policy and flanked by heightened competition.SingTel's share price closed at 7 cents or 2 per cent higher at $3.55 yesterday, while Telstra's gained 3 Australian cents - 0.62 per cent - to A$4.83.迷你倉出租

Source: The Gazette, Cedar Rapids, IowaSept.迷你倉出租 10--A forensic pathologist for the defense disputed state expert witnesses Monday that said 17-month-old Kamryn Schlitter suffered two possible head injuries, one older and one more recent, and the timing of her injuries.Dr. Peter Stephens, a former pathologist who practiced in Cedar Rapids from 1985 to 1995 and also a former deputy state medical examiner, said there was no way to determine if there were two different bleeds from looking at the pathologists' reports in this case. Stephens agreed Kamryn's head trauma caused a sub dural hematoma but said it could have been 24-48 hours old.-- Replay live coverage of Monday's court proceedings: Amy Parmer murder trialThe timing of the injury is crucial to Amy Parmer, who is charged with first-degree murder in Kamryn's death March 28, 2010. Stephens, testifying for the defense, disputed earlier testimony from at least, three doctors who testified for the state, claiming the recent injury occurred within hours to days of when Parmer called 911 for the toddler on March 21, 2010.Parmer was taking care of Kamryn that night from about 5 to 7:30 p.m. when the toddler became unresponsive and started posturing -- involuntary contraction of the limbs, according to testimony.Parmer, 29, of Hiawatha, charged with first-degree murder and child endangerment resulting in death, is accused of inflicting the physical abuse of Kamryn, along with Schlitter, 25, of Cedar Rapids, who was convicted in her death last December and is serving 50 years in prison.Parmer will take the stand 9 a.m. Tuesday in her own defense. The trial may wrap up at the end of the week. Follow Gazette Reporter Trish Mehaffey's continuing live coverage from the courtroom.Stephens directly disputed Dr. Gary Baumbach, a pathologist with UI Hospitals and Clinics in Iowa City, who testified last week. Baumbach claimed the recent injury could have occurred within 12-24 hours of Kamryn's brain surgery March 21, 2010.Baumbach said there was evidence of an older bleed that could have been weeks to months old and a more recent one occurred within 12-24 hours. He said there was evidence the red blood cells hadn't broken down, which indicates it was an "acute event" or recent one. If it was longer than 24 hours, there would be fibroblast cells in the sub dural hematoma, that starts healing the clot, but those were missing, Baumbach said.Stephens said it wasn't possible to say if there was fresh or recent bleed. There is evidence of a breakdown in the blood, which indicates the injury could be 24-48 hours old b迷你倉t it's impossible to age a bleeding as less than 12 hours according to literature regarding this kind of injury. He suggested this could have been a re-bleeding, which would be part of an original bleed.Stephens said Baumbach's report was incomplete because he only had a small sample from the clot.On cross, Stephens admitted he couldn't say with certainty that there wasn't two bleeding events but then said the recent one could have been the result of the surgery.First Assistant Linn County Attorney Nick Maybanks asked Stephens if in his deposition didn't he sayd there could be a mixture of two events."I should have said there could be," Stephens said.In deposition, Stephens said the recent bleed caused Kamryn's collapse, Maybanks said."Yes, it's a possibility," Stephens said.Maybanks then asked in order to have a re-bleeding, wouldn't the blood have to come from blood vessels but none of the doctors said there was evidence of that.Stephens agreed there was no evidence.Stephens on re-direct confirmed the injury was 2 to 3 days old and there's no way to determine two injuries.Earlier in the day, Tyler Johnston, Parmer's attorney, again renewed his motion for mistrial based on a discovery violation, claiming his medical experts were at a disadvantage because Baumbach changed his testimony from his deposition and Zyriah Schlitter's trial. He claimed the state didn't give him that information.According to his testimony, Baumbach changed the timing of the injury to 12-24 hours based on additional reading and research he did on brain hemorrhages.Maybanks argued the state didn't commit a discovery violation. Baumbach didn't change his opinion. He always referenced the possibility of two bleeding events. He did clarify the 12-24 hour window in this trial.Sixth Judicial District Judge Marsha Beckelman said the defense witnesses were allowed to go down last Friday and talk to Baumbach and look at his slides of the brain injury and bleeding."There has been an incredible amount of medical evidence in this case and differing opinions," Beckelman said. "The state asked Dr. Baumbach if he changed his opinion and he said he didn't."Beckelman said it will be up to the jury to determine the credibility of the experts, just like the other witnesses. She didn't believe the state had committed any wrongdoing and denied the motion.Beckelman also denied the defense's motion for a direct verdict of acquittal.Copyright: ___ (c)2013 The Gazette (Cedar Rapids, Iowa) Visit The Gazette (Cedar Rapids, Iowa) at thegazette.com Distributed by MCT Information Services儲存倉

NEW YORK, Sept.迷你倉價錢 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Global Department Stores Market Size and Forecast to 2017 .reportlinker.com/p01610767/Global-Department-Stores-Market--Size-and-Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Department_StoresProduct Synopsis- Future forecasts and historic market data can improve market and strategic planning- Understand which products will be the major winners and losers in the coming years- Assess the impact of economic recession and recovery on market growthIntroduction and LandscapeWhy was the report written?"Global Department Stores Market Size and Forecast to 2017" is based upon an extensive, cross-country, industry research program which brings together Canadean's research, modelling, and analysis expertise in order to develop uniquely detailed market data. It provides detailed quantitative analysis of past and future trends, crucially providing retail sales data of products through Department Stores. Data sets are provided for 2007 through to 2017, with actuals being provided for 2012. All initial market sizing and analysis is conducted in local currency in order to ensure that local trends are reflected in the data before conversion into other currencies.What are the key drivers behind recent market changes?Consumers have been reacting to the effects of the global recession, including the following recovery period on their discretionary spending and retail markets have been no exception. While the country by country market changes have varied, nowhere has been left totally untouched. This report quantitatively examines the components of change in the market by looking at historic and future growth patterns including how changes in consumers' behaviour have affected the retail sector for different product categories through Department Stores.What makes this report unique and essential to read?This report provides detailed data on the size and development of retail sales of individual product types through Department Stores globally. It provides a detailed and comprehensive quantitative analysis of the trends affecting market development through both historic and forecast data.Key Features and BenefitsDetailed category coverage is provided, covering 25 products, across eight product groups that include: Apparel, Accessories and Luxury Goods, Books, News and Stationery, Electricals and Electronics, Food and Grocery, Furniture and Floor Coverings, Home and Garden Products, Music, Video and Entertainment Software, and Sports and Leisure Equipment.Forecasts allow marketers to understand the future pattern of market trends, from winners and losers to category dynamics, and thereby quickly and easily identify the key areas in which they want to compete in the future.Key HighlightsThe top five EU nations: the UK, France, Germany, Russia, and Italy, accounted for more than half of European retail sales through the channel in 2012. Their combined share is expected to decline by 2017.Japan and China together accounted for over 65% of total Asia-Pacific retail sales through the channel in 2012. The countries are expected to command majority sales through to 2017.1 Introduction1.1 What is this Report About?1.2 Definitions1.2.1 This report provides 2012 actual sales; while forecasts are provided for 2013 - 20171.2.2 Product and Channel Definitions1.2.3 Country Coverage1.3 Summary Methodology1.3.1 Overview1.3.2 The triangulated market sizing method1.3.3 Industry surveys in the creation of retail market data1.3.4 Quality control and standardized processes2 Global Department Stores - Overview2.1 Global Channel Growth Dynamics2.2 Global Channel Growth Dynamics2.3 Global Department Stores: Penetration by Region2.4 Global Department Stores: Sales by Product Category2.4.1 Product Group Growth Dynamics in Department Stores2.5 Sales Development by Product Group in Department Stores2.5.1 Sales Growth by Product Categories in Department Stores2.6 Global Department Stores: Sales by Leading Countries2.7 Global Per Capita Spending Analysis in Department Stores2.7.1 Regional Analysis2.7.2 Product Group Analysis2.7.3 Individual Product Category Analysis2.7.4 Top 20 Countries2.8 Channel Hotspots2.8.1 Fastest Growing Countries, by sales in Department Stores2.8.2 Fastest Growing Countries, by Per Capita Spending Growth, in Department Stores2.8.3 Fastest Growing Product Categories in Department Stores3 Asia-Pacific Department Stores - Overview3.1 Asia-Pacific Channel Growth Dynamics3.2 Asia-Pacific Department Stores: Sales by Country3.3 Asia-Pacific Department Stores: Penetration by Country3.4 Asia-Pacific Department Stores: Sales by Product Group3.4.1 Sales Development by Product Group in Department Stores3.4.2 Sales Growth by Product Categories in Department Stores3.5 Asia-Pacific Department Stores: Sales by Leading Country3.6 Asia-Pacific Per Capita Spending Analysis in Department Stores3.6.1 Regional Analysis3.6.2 Product Group Analysis3.6.3 Individual Product Category Analysis3.7 Channel Hotspots3.7.1 Fastest Growing Countries, by sales in Department Stores3.7.2 Fastest Growing Countries, by Per Capita Spending Growth, in Department Stores3.7.3 Top 5 Fastest Growing Product Categories in Department Stores4 Europe Department Stores - Overview4.1 Europe Channel Growth Dynamics4.2 Europe Department Stores: Sales by Country4.3 Europe Department Stores: Penetration by Country4.4 Europe Department Stores: Sales by Product Group4.4.1 Sales Development by Product Group in Department Stores4.4.2 Sales Growth by Product Categories in Department Stores4.5 Europe Department Stores: Sales by Leading Country4.6 Europe Per Capita Spending Analysis in Department Stores4.6.1 Regional Analysis4.6.2 Product Group Analysis4.6.3 Individual Product Category Analysis4.7 Channel Hotspots4.7.1 Fastest Growing Countries, by sales in Department Stores4.7.2 Fastest Growing Countries, by Per Capita Spending Growth, in Department Stores4.7.3 Top 5 Fastest Growing Product Categories in Department Stores5 Latin America Department Stores - Overview5.1 Latin America Channel Growth Dynamics5.2 Latin America Department Stores: Sales by Country5.3 Latin America Department Stores: Penetration by Country5.4 Latin America Department Stores: Sales by Product Group5.4.1 Sales Development by Product Group in Department Stores5.4.2 Sales Growth by Product Categories in Department Stores5.5 Latin America Department Stores: Sales by Leading Country5.6 Latin America Per Capita Spending Analysis in Department Stores5.6.1 Regional Analysis5.6.2 Product Group Analysis5.6.3 Individual Product Category Analysis5.7 Channel Hotspots5.7.1 Fastest Growing Countries, by sales in Department Stores5.7.2 Fastest Growing Countries, by Per Capita Spending Growth, in Department Stores5.7.3 Top 5 Fastest Growing Product Categories in Department Stores6 Middle-East and Africa Department Stores - Overview6.1 Middle-East and Africa Channel Growth Dynamics6.2 Middle-East and Africa Department Stores: Sales by Country6.3 Middle-East and Africa Department Stores: Penetration by Country6.4 Middle-East and Africa Department Stores: Sales by Product Group6.4.1 Sales Development by Product Group in Department Stores6.4.2 Sales Growth by Product Categories in Department Stores6.5 Middle-East and Africa Department Stores: Sales by Leading Country6.6 Middle-East and Africa Spending Analysis in Department Stores6.6.1 Regional Analysis6.6.2 Product Group Analysis6.6.3 Individual Product Category Analysis6.7 Channel Hotspots6.7.1 Fastest Growing Countries, by sales in Department Stores6.7.2 Fastest Growing Countries, by Per Capita Spending Growth, in Department Stores6.7.3 Top 5 Fastest Growing Product Categories in Department Stores7 North America Department Stores - Overview7.1 North America Channel Growth Dynamics7.2 North America Department Stores: Sales by Country7.3 North America Department Stores: Penetration by Country7.4 North America Department Stores: Sales by Product Group7.4.1 Sales Development by Product Group in Department Stores7.4.2 Sales Growth by Product Categories in Department Stores7.5 North America Department Stores: Sales by Leading Country7.6 North America Per Capita Spending Analysis in Department Stores7.6.1 Regional Analysis7.6.2 Product Group Analysis7.6.3 Individual Product Category Analysis7.7 Channel Hotspots8 Appendix8.1 About Canadean8.2 DisclaimerLIST OF TABLESTable 1: Exchange Rate (Annual Average), 2007-2012 Table 2: Exchange Rate (Annual Average), 2013-2017 (Forecasts) Table 3: Canadean Retail Channel Definitions Table 4: Canadean Retail Category Definitions Table 5: Canadean Retail Country Coverage Table 6: Global Department Stores Sales (USD billion), by Region, 2007-2017 Table 7: Global Department Stores Sales (USD billion), by Region, 2007 - 2012 Table 8: Global Department Stores Sales Forecasts (USD billion), by Region, 2012 - 2017 Table 9: Global Department Stores Sales (% Total Market), by Region, 2007 - 2012 Table 10: Global Department Stores sales Forecasts (% Total Market), by Region, 2012 - 2017 Table 11: Global Department Stores Share Of Retail Sales (% of Total Retail sales Within A Region), by Region, 2007 - 2012 Table 12: Global Department Stores Forecast Share Of Retail Sales (% of Total Retail sales Within A Region), by Region, 2012 - 2017 Table 13: Global Department Stores Sales (USD billion), by Product Groups, 2007-2017 Table 14: Global Department Stores Sales (USD billion) by Product Category, 2007 - 2012 Table 15: Global Department Stores Sales Forecasts (USD billion), by Product Category, 2012 - 2017 Table 16: Global Department Stores Sales (USD billion), by Apparel, Accessories, Luggage and Leather Goods Categories, 2007 - 2012 Table 17: Global Department Stores Sales (USD billion), by Apparel, Accessories, Luggage and Leather Goods Categories, 2012 - 2017 Table 18: Global Department Stores Sales (USD billion), by Book, News and Stationery Categories, 2007 - 2012 Table 19: Global Department Stores Sales (USD billion), by Book, News and Stationery Categories, 2012 - 2017 Table 20: Global Department Stores Sales (USD billion), by Electricals and Electronics Categories, 2007 - 2012 Table 21: Global Department Stores Sales (USD billion), by Electricals and Electronics Categories, 2012 - 2017 Table 22: Global Department Stores Sales (USD billion), by Food and Grocery Categories, 2007 - 2012 Table 23: Global Department Stores Sales (USD billion), by Food and Grocery Categories, 2012 - 2017Table 24: Global Department Stores Sales (USD billion), by Furniture and Floor Coverings Category, 2007 - 2012 Table 25: Global Department Stores Sales (USD billion), by Furniture and Floor Coverings Category, 2012 - 2017 Table 26: Global Department Stores Sales (USD billion), by Home and Garden Products Category, 2007 - 2012 Table 27: Global Department Stores Sales (USD billion), by Home and Garden Products Category, 2012 - 2017 Table 28: Global Department Stores Sales (USD billion), by Music and Video and Entertainment Software Category, 2007 - 2012 Table 29: Global Department Stores Sales (USD billion), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 30: Global Department Stores Sales (USD billion), by Sports and Leisure Equipment Category, 2007 - 2012 Table 31: Global Department Stores Sales (USD billion), by Sports and Leisure Equipment Category, 2012 - 2017 Table 32: Global Department Stores Sales (USD billion), Top 20 Countries, 2007 - 2012 Table 33: Global Department Stores Sales (USD billion), Top 20 Countries, 2012 - 2017 Table 34: Global Department Stores Sales (%), Top 20 Countries, 2007 - 2012 Table 35: Global Department Stores Sales (%), Top 20 Countries, 2012 - 2017 Table 36: Global Per Capita Spending in Department Stores (USD), by Region, 2007 - 2012 Table 37: Global Forecast Per Capita Spending in Department Stores (USD), ), by Region,2012 - 2017 Table 38: Global Per Capita Retail Spending (USD), by Product Groups, 2007 - 2012 Table 39: Global Per Capita Retail Spending (USD), by Product Groups, 2012 - 2017 Table 40: Global Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2007 - 2012 Table 41: Global Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2012 - 2017 Table 42: Global Per Capita Spend (USD), by Book, News and Stationery Category, 2007 - 2012 Table 43: Global Per Capita Spend (USD), by Book, News and Stationery Category, 2012 - 2017 Table 44: Global Per Capita Spend (USD), by Electricals and Electronics Category , 2007 - 2012 Table 45: Global Per Capita Spend (USD), by Electricals and Electronics Category, 2012 - 2017 Table 46: Global Per Capita Spend (USD), by Food and Grocery Category, 2007 - 2012 Table 47: Global Per Capita Spend (USD), by Food and Grocery Category, 2012 - 2017 Table 48: Global Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2007 - 2012 Table 49: Global Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2012 - 2017 Table 50: Global Per Capita Spend (USD), by Home and Garden Products Category, 2007 - 2012 Table 51: Global Per Capita Spend (USD), by Home and Garden Products Category, 2012 - 2017 Table 52: Global Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2007 - 2012 Table 53: Global Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 54: Global Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2007 - 2012Table 55: Global Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2012 - 2017 Table 56: Per Capita Retail Spending (USD), by Country, 2007 - 2012 Table 57: Per Capita Retail Spending (USD), by Country, 2012 - 2017 Table 58: Fastest Growing Countries in Retail Sales (USD billion), by Country, 2007 - 2012 Table 59: Fastest Growing Countries in Retail Sales (USD billion), by Country, 2012 - 2017 Table 60: Fastest Growing Per Capita Retail Spending (USD), by Country, 2007 - 2012 Table 61: Fastest Growing Per Capita Retail Spending (USD), by Country, 2012 - 2017 Table 62: Fastest Growing Countries in Department Stores , by Sales, (USD billion) Table 63: Fastest Growing Product Categories in Department Stores (USD billion) by Sales Growth, 2007 - 2012 Table 64: Fastest Growing Product Categories in Department Stores (USD billion) by Sales Growth, 2012 - 2017 Table 65: Asia-Pacific Department Stores Sales (USD million), by Country, 2007-2017 Table 66: Asia-Pacific Department Stores Sales (USD million), by Country, 2007 - 2012 Table 67: Asia-Pacific Department Stores Sales (USD million), by Country, 2012 - 2017 Table 68: Asia-Pacific Department Stores Sales (% Total Market), by Region, 2007 - 2012 Table 69: Asia-Pacific Department Stores Sales (% Total Market), by Region, 2012 - 2017 Table 70: Asia-Pacific Department Stores Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2007 - 2012 Table 71: Asia-Pacific Department Stores Forecast Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2012 - 2017 Table 72: Asia-Pacific Department Stores Sales (USD million), by Product Groups, 2007-2017 Table 73: Asia-Pacific Department Stores Sales (USD million) by Product Group, 2007 - 2012 Table 74: Asia-Pacific Department Stores Sales (USD million) by Product Group, 2012 - 2017 Table 75: Asia-Pacific Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2007 - 2012 Table 76: Asia-Pacific Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2012 - 2017 Table 77: Asia-Pacific Department Stores Sales (USD million), by Book, News and Stationery Categories, 2007 - 2012 Table 78: Asia-Pacific Department Stores Sales (USD million), by Book, News and Stationery Categories, 2012 - 2017 Table 79: Asia-Pacific Department Stores Sales (USD million), by Electricals and Electronics Categories, 2007 - 2012 Table 80: Asia-Pacific Department Stores Sales (USD million), by Electricals and Electronics Categories, 2012 - 2017 Table 81: Asia-Pacific Department Stores Sales (USD million), by Food and Grocery Categories, 2007 - 2012 Table 82: Asia-Pacific Department Stores Sales (USD million), by Food and Grocery Categories, 2012 - 2017 Table 83: Asia-Pacific Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2007 - 2012 Table 84: Asia-Pacific Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2012 - 2017 Table 85: Asia-Pacific Department Stores Sales (USD million), by Home and Garden Products Category, 2007 - 2012 Table 86: Asia-Pacific Department Stores Sales (USD million), by Home and Garden Products Category, 2012 - 2017 Table 87: Asia-Pacific Department Stores Sales (USD million) by Music and Video and Entertainment Software Categories, 2007 - 2012 Table 88: Asia-Pacific Department Stores Sales (USD million), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 89: Asia-Pacific Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2007 - 2012 Table 90: Asia-Pacific Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2012 - 2017 Table 91: Asia-Pacific Department Stores Sales (USD million) by Country, 2007 - 2012 Table 92: Asia-Pacific Department Stores Sales (USD million) by Country, 2012 - 2017 Table 93: Asia-Pacific Department Stores Sales (%), by Leading Countries, 2007 - 2012 Table 94: Asia-Pacific Department Stores Sales (%), by Leading Countries, 2012 - 2017 Table 95: Asia-Pacific Per Capita Spending in Department Stores (USD), by Country, 2007 - 2012 Table 96: Asia-Pacific Forecast Per Capita Spending in Department Stores (USD), by Country, 2012 - 2017Table 97: Asia-Pacific Per Capita Retail Spending (USD), by Product Groups, 2007 - 20迷你倉最平2 Table 98: Asia-Pacific Per Capita Retail Spending (USD), by Product Groups, 2012 - 2017 Table 99: Asia-Pacific Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2007 - 2012 Table 100: Asia-Pacific Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2012 - 2017 Table 101: Asia-Pacific Per Capita Spend (USD), by Book, News and Stationery Category, 2007 - 2012 Table 102: Asia-Pacific Per Capita Spend (USD), by Book, News and Stationery Category, 2012 - 2017 Table 103: Asia-Pacific Per Capita Spend (USD), by Electricals and Electronics Category, 2007 - 2012 Table 104: Asia-Pacific Per Capita Spend (USD), by Electricals and Electronics Category, 2012 - 2017 Table 105: Asia-Pacific Per Capita Spend (USD), by Food and Grocery Category, 2007 - 2012 Table 106: Asia-Pacific Per Capita Spend (USD), by Food and Grocery Category, 2012 - 2017 Table 107: Asia-Pacific Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2007 - 2012 Table 108: Asia-Pacific Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2012 - 2017 Table 109: Asia-Pacific Per Capita Spend (USD), by Home and Garden Products Category, 2007 - 2012 Table 110: Asia-Pacific Per Capita Spend (USD), by Home and Garden Products Category, 2012 - 2017 Table 111: Asia-Pacific Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2007 - 2012 Table 112: Asia-Pacific Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 113: Asia-Pacific Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2007 - 2012 Table 114: Asia-Pacific Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2012 - 2017Table 115: Asia-Pacific Fastest Growing Countries in Retail Sales (USD million), by Country, 2007 - 2012 Table 116: Asia-Pacific Fastest Growing Countries in Retail Sales (USD million), by Country, 2012 - 2017 Table 117: Asia-Pacific Per Capita Retail Spending (USD), by Country, 2007 - 2012 Table 118: Asia-Pacific Per Capita Retail Spending (USD), by Country, 2012 - 2017 Table 119: Asia-Pacific Top 5 Fastest Growing Product Categories in Department Stores (USD million) by Sales Growth, 2007 - 2012 Table 120: Asia-Pacific Top 5 Fastest Growing Product Categories in Department Stores (USD million) by Sales Growth, 2012 - 2017 Table 121: Europe Department Stores Sales (USD million), by Country, 2007-2017 Table 122: Europe Department Stores Sales (USD million), by Country, 2007 - 2012 Table 123: Europe Department Stores Sales (USD million), by Country, 2012 - 2017 Table 124: Europe Department Stores Sales (% Total Market), by Region, 2007 - 2012 Table 125: Europe Department Stores Sales (% Total Market), by Region, 2012 - 2017 Table 126: Europe Department Stores Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2007 - 2012 Table 127: Europe Department Stores Forecast Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2012 - 2017 Table 128: Europe Department Stores Sales (USD million), by Product Groups, 2007-2017 Table 129: Europe Department Stores Sales (USD million) by Product Group, 2007 - 2012 Table 130: Europe Department Stores Sales (USD million) by Product Group, 2012 - 2017 Table 131: Europe Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2007 - 2012 Table 132: Europe Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2012 - 2017 Table 133: Europe Department Stores Sales (USD million), by Book, News and Stationery Categories, 2007 - 2012 Table 134: Europe Department Stores Sales (USD million), by Book, News and Stationery Categories, 2012 - 2017 Table 135: Europe Department Stores Sales (USD million), by Electricals and Electronics Categories, 2007 - 2012 Table 136: Europe Department Stores Sales (USD million), by Electricals and Electronics Categories, 2012 - 2017 Table 137: Europe Department Stores Sales (USD million), by Food and Grocery Categories, 2007 - 2012 Table 138: Europe Department Stores Sales (USD million), by Food and Grocery Categories, 2012 - 2017 Table 139: Europe Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2007 - 2012 Table 140: Europe Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2012 - 2017 Table 141: Europe Department Stores Sales (USD million), by Home and Garden Products Category, 2007 - 2012 Table 142: Europe Department Stores Sales (USD million), by Home and Garden Products Category, 2012 - 2017 Table 143: Europe Department Stores Sales (USD million) by Music and Video and Entertainment Software Categories, 2007 - 2012 Table 144: Europe Department Stores Sales (USD million), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 145: Europe Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2007 - 2012Table 146: Europe Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2012 - 2017 Table 147: Europe Department Stores Sales (USD million) by Country, 2007 - 2012 Table 148: Europe Department Stores Sales (USD million) by Country, 2012 - 2017 Table 149: Europe Department Stores Sales (%), by Leading Countries, 2007 - 2012 Table 150: Europe Department Stores Sales (%), by Leading Countries, 2012 - 2017 Table 151: Europe Per Capita Spending in Department Stores (USD), by Country, 2007 - 2012 Table 152: Europe Forecast Per Capita Spending in Department Stores (USD), by Country, 2012 - 2017 Table 153: Europe Per Capita Retail Spending (USD), by Product Groups, 2007 - 2012 Table 154: Europe Per Capita Retail Spending (USD), by Product Groups, 2012 - 2017 Table 155: Europe Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2007 - 2012 Table 156: Europe Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2012 - 2017 Table 157: Europe Per Capita Spend (USD), by Book, News and Stationery Category, 2007 - 2012 Table 158: Europe Per Capita Spend (USD), by Book, News and Stationery Category, 2012 - 2017 Table 159: Europe Per Capita Spend (USD), by Electricals and Electronics Category, 2007 - 2012 Table 160: Europe Per Capita Spend (USD), by Electricals and Electronics Category, 2012 - 2017 Table 161: Europe Per Capita Spend (USD), by Food and Grocery Category, 2007 - 2012 Table 162: Europe Per Capita Spend (USD), by Food and Grocery Category, 2012 - 2017 Table 163: Europe Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2007 - 2012 Table 164: Europe Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2012 - 2017 Table 165: Europe Per Capita Spend (USD), by Home and Garden Products Category, 2007 - 2012 Table 166: Europe Per Capita Spend (USD), by Home and Garden Products Category, 2012 - 2017 Table 167: Europe Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2007 - 2012 Table 168: Europe Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 169: Europe Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2007 - 2012 Table 170: Europe Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2012 - 2017 Table 171: Europe Fastest Growing Countries in Retail Sales (USD million), by Country, 2007 - 2012 Table 172: Europe Fastest Growing Countries in Retail Sales (USD million), by Country, 2012 - 2017 Table 173: Europe Per Capita Retail Spending (USD), by Country, 2007 - 2012 Table 174: Europe Per Capita Retail Spending (USD), by Country, 2012 - 2017 Table 175: Europe Top 5 Fastest Growing Product Categories in Department Stores (USD million) by Sales Growth, 2007 - 2012 Table 176: Europe Top 5 Fastest Growing Product Categories in Department Stores (USD million) by Sales Growth, 2012 - 2017 Table 177: Latin America Department Stores Sales (USD million), by Country, 2007-2017 Table 178: Latin America Department Stores Sales (USD million), by Country, 2007 - 2012 Table 179: Latin America Department Stores Sales (USD million), by Country, 2012 - 2017 Table 180: Latin America Department Stores Sales (% Total Market), by Region, 2007 - 2012 Table 181: Latin America Department Stores Sales (% Total Market), by Region, 2012 - 2017 Table 182: Latin America Department Stores Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2007 - 2012 Table 183: Latin America Department Stores Forecast Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2012 - 2017 Table 184: Latin America Department Stores Sales (USD million), by Product Groups, 2007-2017 Table 185: Latin America Department Stores Sales (USD million) by Product Group, 2007 - 2012 Table 186: Latin America Department Stores Sales (USD million) by Product Group, 2012 - 2017 Table 187: Latin America Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2007 - 2012Table 188: Latin America Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2012 - 2017 Table 189: Latin America Department Stores Sales (USD million), by Book, News and Stationery Categories, 2007 - 2012 Table 190: Latin America Department Stores Sales (USD million), by Book, News and Stationery Categories, 2012 - 2017 Table 191: Latin America Department Stores Sales (USD million), by Electricals and Electronics Categories, 2007 - 2012 Table 192: Latin America Department Stores Sales (USD million), by Electricals and Electronics Categories, 2012 - 2017 Table 193: Latin America Department Stores Sales (USD million), by Food and Grocery Categories, 2007 - 2012 Table 194: Latin America Department Stores Sales (USD million), by Food and Grocery Categories, 2012 - 2017 Table 195: Latin America Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2007 - 2012 Table 196: Latin America Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2012 - 2017 Table 197: Latin America Department Stores Sales (USD million), by Home and Garden Products Category, 2007 - 2012 Table 198: Latin America Department Stores Sales (USD million), by Home and Garden Products Category, 2012 - 2017 Table 199: Latin America Department Stores Sales (USD million) by Music and Video and Entertainment Software Categories, 2007 - 2012 Table 200: Latin America Department Stores Sales (USD million), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 201: Latin America Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2007 - 2012 Table 202: Latin America Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2012 - 2017 Table 203: Latin America Department Stores Sales (USD million) by Country, 2007 - 2012 Table 204: Latin America Department Stores Sales (USD million) by Country, 2012 - 2017 Table 205: Latin America Department Stores Sales (%), by Leading Countries, 2007 - 2012 Table 206: Latin America Department Stores Sales (%), by Leading Countries, 2012 - 2017 Table 207: Latin America Per Capita Spending in Department Stores (USD), by Country, 2007 - 2012Table 208: Latin America Forecast Per Capita Spending in Department Stores (USD), by Country, 2012 - 2017 Table 209: Latin America Per Capita Retail Spending (USD), by Product Groups, 2007 - 2012 Table 210: Latin America Per Capita Retail Spending (USD), by Product Groups, 2012 - 2017 Table 211: Latin America Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2007 - 2012 Table 212: Latin America Per Capita Spend (USD), by Apparel, Accessories, Luggage and Leather Goods Category, 2012 - 2017 Table 213: Latin America Per Capita Spend (USD), by Book, News and Stationery Category, 2007 - 2012 Table 214: Latin America Per Capita Spend (USD), by Book, News and Stationery Category, 2012 - 2017 Table 215: Latin America Per Capita Spend (USD), by Electricals and Electronics Category, 2007 - 2012 Table 216: Latin America Per Capita Spend (USD), by Electricals and Electronics Category, 2012 - 2017 Table 217: Latin America Per Capita Spend (USD), by Food and Grocery Category, 2007 - 2012 Table 218: Latin America Per Capita Spend (USD), by Food and Grocery Category, 2012 - 2017 Table 219: Latin America Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2007 - 2012 Table 220: Latin America Per Capita Spend (USD), by Furniture and Floor Coverings Category, 2012 - 2017 Table 221: Latin America Per Capita Spend (USD), by Home and Garden Products Category, 2007 - 2012 Table 222: Latin America Per Capita Spend (USD), by Home and Garden Products Category, 2012 - 2017 Table 223: Latin America Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2007 - 2012 Table 224: Latin America Per Capita Spend (USD), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 225: Latin America Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2007 - 2012Table 226: Latin America Per Capita Spend (USD), by Sports and Leisure Equipment Category, 2012 - 2017 Table 227: Latin America Fastest Growing Countries in Retail Sales (USD million), by Country, 2007 - 2012 Table 228: Latin America Fastest Growing Countries in Retail Sales (USD million), by Country, 2012 - 2017 Table 229: Latin America Per Capita Retail Spending (USD), by Country, 2007 - 2012 Table 230: Latin America Per Capita Retail Spending (USD), by Country, 2012 - 2017 Table 231: Latin America Top 5 Fastest Growing Product Categories in Department Stores (USD million) by Sales Growth, 2007 - 2012 Table 232: Latin America Top 5 Fastest Growing Product Categories in Department Stores (USD million) by Sales Growth, 2012 - 2017 Table 233: Middle-East and Africa Department Stores Sales (USD million), by Country, 2007-2017 Table 234: Middle-East and Africa Department Stores Sales (USD million), by Country, 2007 - 2012 Table 235: Middle-East and Africa Department Stores Sales (USD million), by Country, 2012 - 2017 Table 236: Middle-East and Africa Department Stores Sales (% Total Market), by Region, 2007 - 2012 Table 237: Middle-East and Africa Department Stores Sales (% Total Market), by Region, 2012 - 2017 Table 238: Middle-East and Africa Department Stores Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2007 - 2012 Table 239: Middle-East and Africa Department Stores Forecast Share Of Retail Sales (% of Total Retail sales Within A Country), by Country, 2012 - 2017 Table 240: Middle-East and Africa Department Stores Sales (USD million), by Product Groups, 2007-2017 Table 241: Middle-East and Africa Department Stores Sales (USD million) by Product Group, 2007 - 2012 Table 242: Middle-East and Africa Department Stores Sales (USD million) by Product Group, 2012 - 2017 Table 243: Middle-East and Africa Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2007 - 2012 Table 244: Middle-East and Africa Department Stores Sales (USD million), by Apparel, Accessories, Luggage and Leather Goods Categories, 2012 - 2017 Table 245: Middle-East and Africa Department Stores Sales (USD million), by Book, News and Stationery Categories, 2007 - 2012Table 246: Middle-East and Africa Department Stores Sales (USD million), by Book, News and Stationery Categories, 2012 - 2017 Table 247: Middle-East and Africa Department Stores Sales (USD million), by Electricals and Electronics Categories, 2007 - 2012 Table 248: Middle-East and Africa Department Stores Sales (USD million), by Electricals and Electronics Categories, 2012 - 2017 Table 249: Middle-East and Africa Department Stores Sales (USD million), by Food and Grocery Categories, 2007 - 2012 Table 250: Middle-East and Africa Department Stores Sales (USD million), by Food and Grocery Categories, 2012 - 2017 Table 251: Middle-East and Africa Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2007 - 2012 Table 252: Middle-East and Africa Department Stores Sales (USD million), by Furniture and Floor Coverings Category, 2012 - 2017 Table 253: Middle-East and Africa Department Stores Sales (USD million), by Home and Garden Products Category, 2007 - 2012 Table 254: Middle-East and Africa Department Stores Sales (USD million), by Home and Garden Products Category, 2012 - 2017 Table 255: Middle-East and Africa Department Stores Sales (USD million) by Music and Video and Entertainment Software Categories, 2007 - 2012 Table 256: Middle-East and Africa Department Stores Sales (USD million), by Music and Video and Entertainment Software Category, 2012 - 2017 Table 257: Middle-East and Africa Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2007 - 2012 Table 258: Middle-East and Africa Department Stores Sales (USD million), by Sports and Leisure Equipment Category, 2012 - 2017 Table 259: Middle-East and Africa Department Stores Sales (USD million) by Country, 2007 - 2012 Table 260: Middle-East and Africa Department Stores Sales (USD million) by Country, 2012 - 2017 Table 261: Middle-East and Africa Department Stores Sales (%), by Leading Countries, 2007 - 2012 Table 262: Middle-East and Africa Department Stores Sales (%), by Leading Countries, 2012 - 2017 Table 263: Middle-East and Africa Per Capita Spending in Department Stores (USD), by Country, 2007 - 2012 Table 264: Middle-East andTo order this report: Global Department Stores Market Size and Forecast to 2017 .reportlinker.com/p01610767/Global-Department-Stores-Market--Size-and-Forecast-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Department_Stores__________________________Contact Clare: clare@reportlinker.com US: (339)-368-6001Intl: +1 339-368-6001ReportlinkerWeb site: .reportlinker.com/迷你倉

The float of the mainland company, backed by Cheng Yu-tung, would be HK’s biggest in monthsChina Huishan Dairy, in which Hong Kong business mogul Cheng Yu-tung has a roughly 25 per cent stake, plans to raise up to US$1.迷你倉價錢3 billion through a float in Hong Kong that is poised to be the city’s largest initial public offering since June.The firm, based in Shenyang, Liaoning province, runs vertically integrated operations in the milk supply chain, from cow breeding to manufacturing.It plans to sell 3.79 billion shares at an indicative price range of HK$2.28 to HK$2.67 each, translating into an expected price-earnings ratio of 14.5 to 17 times next year’s forecast earnings, a document seen by the South China Morning Post showsThe deal has captured at least three cornerstone investors – Yili Group, Cofco Agricultural and Norges Bank, which manages the Norwegian government’s pension fund – to buy US$220 million of shares, representing about a 10th of the entire IPO.The firm will begin a global roadshow today and take orders from institutional investors at the same time. Its shares were scheduled to be listed late this month, bankers involved in the deal said.If successful, Huisha迷你倉最平 will join five dairy firms listed on the Hong Kong stock exchange – including China Mengniu Dairy and China Modern Dairy – which are trading on an average price-earnings ratio of 24, based on next year’s forecast earnings, and a price-book ratio of 1.5 times.Founded in 1951, Huishan has been looking to sell shares in Hong Kong for the past three years following a toxic milk scandal on the mainland in 2008, when melamine-tainted dairy products killed at least six infants and made thousands of babies ill.Huishan’s annual production of raw milk reached two million tonnes, and output of baby formula powder totalled 240,000 tonnes last year, the firm’s website says. It owns 400,000 cows and runs six advanced manufacturing plants in Liaoning.Following a spring thaw that included a handful of big offerings, including two listings of state-owned enterprises that each raised more than US$1 billion, Hong Kong’s IPO market – which had been the world’s top capital-raising venue for three consecutive years to 2011 – has been quiet for several months.Market sentiment for new shares has been dented by concerns about a winding down of US monetary stimulus and a slowdown on the mainland.迷你倉

Source: Connecticut Post, BridgeportSept.mini storage 09--In a city where even the trees are tough, the annual bloodbath of a Bridgeport Democratic primary is set for Tuesday.Among seats being contested are those on the Bridgeport Board of Education, a group whose meetings in recent times have had all the decorum of a WWE cage match.And while the adults engage in their smackdowns, leg holds and half-nelsons, the years continue to move by for Bridgeport school children in a failing system.They move on, from grade to grade, ants marching, as Dave Matthews might say, while the adults settle their scores.Oh, well.Primaries will take place also in a number of City Council districts.Stop the presses: there have been reports in recent days that absentee ballot fraud may be at play. Imagine.Another report said that Mayor Bill Finch was meddling in the City Council elections.Well, why wouldn't he? Part of the reason why he is mayor is that he wants to be in control.There are no Marquis of Queensbury rules in politics, here or anywhere else. No one said the fight has to be fair.The goal in these elections is to win, to amass power; not to win a trophy for soaring eloquence or the presentation of noble ideas.Whether it's the primary or the general election, the only thing that counts at the end of the day is how many of your people voted. Numbers have no nuance. 150 is more than 149 and that's that.Though there are no Marquis of Queensbury rules, there are, of course, laws that govern elections. Over the years, Bridgeport politicians, usually Democrats, have merrily ignored many of those laws.The handling of absentee ballots is one area in which imaginative partisans in Bridgeport have always excelled.The lonely linoleum hallways of senior citizen housing, alas, have always been low-hanging fruit for the absentee ballot zealots.Many year ago, an elderly, confused -- but quite feisty -- woman in a Bridgeport nursing home told me she'd signed some insurance forms that had been presented to her by the administrator of the facility.She hadn't signed insurance forms; she'd signed a voter registration form and an application for an absentee ballself storaget that was later filled out on her behalf by someone else.A 103-year-old blind woman in this same facility did the same thing: some operative had given her a voter registration form and directed the old woman's hand to a line where she made her mark of acquiescence: a squiggly "X."The same "X" appeared on an application for an absentee ballot.The year, by the way, was 1975. You think much has changed? Don't bet on it. Over the years, Bridgeport politicians have been sued, fined, banned from political activity and punished by state election officials in a variety of ways.It means nothing.The stakes are such -- jobs, primarily -- that it's all worth it.Last November, Mayor Bill Finch backed a referendum question that would have eliminated an elected school board and allowed the mayor to appoint the board. To the surprise of many, myself included, the opposition to that proposal actually took to the streets and won the numbers game.So, entrenched interests can be beat. It takes hard work, of course, and it's close-quarters combat, not always overseen by an impartial referee. In short, it's not always a fair fight.Now, about those trees: In one of the more twisted acts of vandalism in the city, someone went out with a chain saw in the middle of a gale in March 2010 and tried to inflict fatal wounds on some sycamore trees that dot the point at St. Mary's-by-the-Sea.The nut job went tree by tree cutting a one inch ring around the trunks. Predictions for their future were dire. The incisions, the experts said, would prevent the trees from sending nutrition from the roots to the branches and leaves above the incisions.But at least eight of the damaged trees were standing, fully leafed and stately the other day. One of them survived not only the chain saw attack of 2010, but the subsequent drilling of a bolt into it for a municipal sign that says the park closes at sunset.No arrest was ever made.mdaly@ctpost.com; 203-330-6394; twitter.com/michaeljdalyctpCopyright: ___ (c)2013 the Connecticut Post (Bridgeport, Conn.) Visit the Connecticut Post (Bridgeport, Conn.) at .ctpost.com Distributed by MCT Information Services迷你倉

SAN JOSE, Calif.儲存倉, Sept. 9, 2013 /PRNewswire/ -- The eBeam Initiative, a forum dedicated to the education and promotion of new semiconductor manufacturing approaches based on electron beam (eBeam) technologies, today announced the completion of the second annual eBeam Initiative survey. 28 member companies from across the photomask supply chain participated in the survey. Participants provided their opinions on a variety of topics critical to advanced photomask production, including the implementation of multibeam mask writing, mask write times at the 10-nm node, adoption of eight-inch and larger photomasks, the future of EUV lithography, and the adoption of general purpose graphics processing unit (GPGPU) solutions for simulation-intensive electronic design automation (EDA) applications. The complete results of the survey will be presented on September 10 during the eBeam Initiative's annual members meeting at the SPIE Photomask Technology Conference in Monterey, Calif.Select Highlights from eBeam Initiative SurveyAmong the highlights of the survey, an overwhelming majority (86 percent) of respondents predict that multibeam mask writers will be in production by 2016 to address the critical problem of increasing mask write times--a 12 percent increase compared to last year's survey. Additionally, a strong majority (76 percent) predict mask critical dimension uniformity (CDU) will be an issue in 2015, with 33 percent of respondents believing mask data preparation (MDP) will need to take mask CDU into account as early as next year.75 percent of respondents also believe that by 2020 some simulation-intensive software applications in EDA will require GPGPUs. Hitachi High-Technologies, which joined the eBeam Initiative as a new member earlier this month, will present results using GPGPU-based computational methods to speed verification of mask layouts that use overlapping eBeam shots at the eBeam Initiative's members meeting tomorrow."I want to thank the many eBeam Initiative members that participated in our second annual survey. The feedback that we received from luminaries on topics critical to the semiconductor and photomask industry has been helpful in confirming key areas to align our efforts on in guiding the industry ecosystem forward in supporting the introduction of new eB迷你倉價錢am technologies," stated Aki Fujimura, CEO of D2S, the managing company sponsor of the eBeam Initiative. "At the same time, I would like to welcome Hitachi High-Technologies as a new member of the eBeam Initiative. As a leader in semiconductor metrology and inspection, Hitachi High-Technologies Group has the equipment, applications and measurement techniques needed to meet critical measurement challenges for sub-28-nm processes, including measurement of wafer CDU. They also bring invaluable experience in leveraging GPGPU-based technology to address the ever-growing challenge of mask write times."The complete results of the eBeam Initiative survey will be available on Wednesday, September 11 for download at .ebeam.orgAbout The eBeam InitiativeThe eBeam Initiative provides a forum for educational and promotional activities regarding new semiconductor manufacturing approaches based on electron beam (eBeam) technologies. The goals of the Initiative are to reduce the barriers to adoption to enable more integrated circuit (IC) design starts and faster time-to-market while increasing the investment in eBeam technologies throughout the semiconductor ecosystem. Members and advisors, which span the semiconductor ecosystem, include: Abeam Technologies, Advantest, Alchip Technologies, AMTC, Applied Materials, Artwork Conversion, Aselta Nanographics, Cadence Design Systems, CEA-Leti, D2S, Dai Nippon Printing, EQUIcon Software GmbH Jena, eSilicon Corporation, Fastrack Design, Fraunhofer CNT, Fujitsu Semiconductor Limited, GenISys GmbH, GLOBALFOUNDRIES, Grenon Consulting, Hitachi High-Technologies, HOYA Corporation, IMS CHIPS, IMS Nanofabrication AG, JEOL, KLA-Tencor, Mentor Graphics Corporation, Multibeam Corporation, NCS, NuFlare Technology, John Chen from NVIDIA, Petersen Advanced Lithography, Colin Harris from PMC-Sierra, Riko Radojcic from Qualcomm, Samsung Electronics, STMicroelectronics, Synopsys, tau-Metrix, Tela Innovations, TOOL Corporation, Toppan Printing, Vistec Electron Beam Lithography Group, and Hugh Durdan from Xilinx. Membership is open to all companies and institutions throughout the electronics industry. To find out more, please visit .ebeam.org.The eBeam InitiativeCONTACT: David Moreno, MCA, Tel: +1-650-968-8900, ext. 125, E-mail:dmoreno@mcapr.comWeb site: .ebeam.org/迷你倉最平

NEW YORK, Sept.自存倉 9, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:Leading Anti-Cancer Drugs and Associated Market 2013-2023 .reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_MedicationReport DetailsCancer treatments - here's your guide to R&D and sales potentialsDo you want to assess the future of cancer medicines? Visiongain's updated report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, R&D trends, opportunities, and outlooks.In that work you see forecasted sales to 2023 at overall world market, submarket, product, and national level. You also assess emerging trends, technologies, and expected drugs.You see what shapes that industry and find its revenue prospectsDiscover, then, what the future holds for anti-cancer products. Read on to explore that industry and see what its future market could be worth.Forecasts to 2023 and other analyses show you commercial potentialsBesides revenue forecasting to 2023, you find historical data, growth rates, and market shares. You assess quantitative and qualitative analysis, business news, outlooks, and developments (R&D). You also gain 114 tables, 47 charts, and three interviews.Is finding data for cancer treatment a challenge? Our work lets you investigate the most promising and lucrative parts of applied oncology, helping you stay ahead in knowledge. That way, you reduce your risk of missing out. Finding data you need has just got easier.Many opportunities remain for cancer-treating drugs. Now see how you can benefit your research, analyses, and decisions there.The following sections show, then, how you benefit from our new investigation and analysis.Discover outlooks for the world market and submarketsAlong with prediction of overall world market value to 2023, our report shows you revenue forecasting of four submarkets at world level:-- Immunotherapies-- Targeted therapies-- Hormone-based agents-- Chemotherapies.Also our study discusses what stimulates and restrains business. That analysis helps you identify potential and find ways for your business to develop. Assess leading brands too.See forecasts for the leading 25 cancer-treating drugsHow will leading drugs perform to 2023 at world level? Our study forecasts individual revenues of the top 25 anti-cancer agents, including these products:-- Rituxan-- Herceptin-- Avastin-- Gleevec-- Revlimid-- Alimta-- Velcade.There you discover how high sales can go, to 2023, finding drugs and years with highest predicted growth and revenues. You see what's happening, then, understanding trends, competition, challenges, and opportunities. Also, assess drugs approved from 2012 to 2013.You find geographical revenue predictions too.Leading national markets - where lie highest revenues and growth? Developments worldwide expand the cancer drugs market, especially rising demand for medicines in emerging countries. China, India, Russia, and Brazil underpin revenue growth.In developed and developing countries, opportunities for pharma companies will occur from 2013. See where and how.Our analyses show you individual revenue forecasts to 2023 for 11 national markets:-- US-- Japan-- Germany, France, UK, Italy, and Spain (EU5)-- Brazil, Russia, India, and China (BRIC).You find potential. Our analyses show growth will occur in established pharma markets and in developing countries. In particular, drug launches from 2013 to 2023 will change medical prescribing and the commercial landscape.Research and development - assess innovation, trends, and possibilitiesWhat's happening in oncological R&D? You see trends for treating these cancers:-- Bladder-- Brain-- Breast-- Cervix-- Gut-- Kidney-- Leukaemia-- Liver-- Lung.Our study also discusses products in development for these cancers:-- Lymphoma-- Multiple myeloma-- Ovary-- Pancreas-- Prostate-- Sarcoma and skin-- Stomach-- Other cancers.R&D in oncology holds strength, variety, and promise. You assess innovations, hearing about developments and finding their significance. Discover progress.For large companies and specialty pharma firms there exist many opportunities. Our study explains, discussing issues to help your work. Also, see what shapes the market from 2013.What affects the industry and market for anti-cancer drugs? Our report discusses issues and events affecting that industry and market from 2013, including these:-- Epidemiology - incidence, prevalence, mortality, and survival-- Tumour (tumor) resistance, heterogeneity, and other medical challenges-- Personalised medicine, live licensing, and theranostics-- Cost-effectiveness, pricing, and reimbursement-- Payers and healthcare policy.The study also discusses other aspects of cancer treatment, including these:-- Monoclonal antibodies (mAbs), cancer vaccines, and other technologies-- Efficacy, toxicity, and alternative treatments-- Biosimilars (follow-on-protein products) and generics-- Pharmacogenomics and genome screening-- Biomarkers and diagnostics.That way, you explore technological, economic, social, and political (STEP) questions, assessing outlooks for the business. You also analyse the anti-cancer drug industry's strengths, weaknesses, opportunities, and threats (SWOT).See, then, what the future holds.Leading companies in cancer treatment and 2017 market valueFrom 2013, new treatments hold great potential for investment, technological advances and high revenues. Our report predicts the world market for anti-cancer agents will reach $116.5bn in 2017, and expand further to 2023.Our analyses show you what technologies, products, and organisations hold greatest potential. They cover these leading companies, among others:-- Roche-- Novartis-- Celgene-- AstraZeneca-- Eli Lilly-- Merck & Co.Prospects for R&D in oncology are strong, and from 2013 there will arise many opportunities. Our work shows you possibilities, helping you stay ahead.Nine ways Leading Anti-Cancer Drugs and Associated Market 2013-2023 helps youIn particular, then, our investigation gives you the following knowledge:-- Revenue to 2023 for the world anti-cancer drugs market - discover that industry's overall sales potential-- Revenues to 2023 for 4 world-level submarkets - investigate the potential of its components, finding the most promising places for investments and revenues-- Revenues to 2023 for 25 leading products - find sales outlooks for top brands, seeing how they can compete and succeed-- Forecasts to 2023 for 11 leading national markets in the Americas, Europe, and Asia - discover the best countries for revenues and potential growth-- Assessments of leading companies - hear about participants' activities, capabilities, results, and outlooks-- Review of R&D in oncology - explore progress in research and development, finding technological and clinical possibilities-- Interviews with authorities in the field - discover debates and opinions to help you stay ahead-- Analysis of what stimulates and restrains that industry and market - assess challenges and strengths, helping you compete and get advantages-- Competition and opportunities - investigate what shapes that market's future, including ways to develop business.You gain information found nowhere elseThat work gives independent analysis. You receive business intelligence found only in our report, seeing where prospects are most rewarding.With our study you are less likely to fall behind in knowledge or miss opportunity. See there how you could benefit your research, analyses, and decisions, also saving time.Discover potential now in anti-cancer medicines and see what you can gain.Ordering now lets you discover opportunities and predictions for cancer treatmentsOur new study is for everyone analysing the industry and market for pharmaceutical biotechnology and cancer medicines. There you find data, trends, opportunities, and predictions. Avoid missing out - please order our report now.Visiongain is a trading partner with the US Federal GovernmentCCR Ref number: KD4R6Table of Contents1. Executive Summary1.1 Overview of Findings1.2 Chapter Breakdown1.3 Research and Analysis Methods1.4 Scope of the Report2. Introduction to Cancer Treatment2.1 The Physiology of Cancer - Causes and Effects2.1.1 Uncontrolled Growth2.1.2 Dedifferentiation2.1.3 Invasiveness and Metastasis2.1.4 Causes of Cancer2.2 The Incidence and Prevalence of Cancer - Rapid Global Growth2.2.1 Incidence2.2.2 Mortality2.2.3 Survival - Improving Odds2.2.3.1 The Developed World2.2.3.2 The Developing World - More Must Be Done2.3 Treating Tumours - How Can We Fight Back?2.3.1 Chemotherapy - The Traditional Treatment2.3.2 Hormone Therapies2.3.3 Immunotherapy - A Magic Bullet2.3.3.1 Monoclonal Antibodies (mAbs)2.3.3.2 Cancer Vaccines2.3.3.3 Non-Specific Immunotherapies2.3.4 Targeted Therapies2.3.5 Differentiating Agents3. World Anti-Cancer Drug Market, 2013-20233.1 Immunotherapies' Market Domination in 20123.2 Global Anti-Cancer Drugs Market Forecast, 2013-20233.3 Immunotherapy Market Forecast, 2013-2023 -The Fastest Growing Anti-Cancer Segment3.4 Targeted Therapy Market Forecast, 2013-2023 - Another Robust Driver of Growth3.5 Hormone Therapy Forecast, 2013-2023 - Dependably Solid3.6 Chemotherapy Market Forecast, 2013-2023 - A Major Contributor4. Leading National Markets, 2013-20234.1 Anti-Cancer Drugs - Leading National Markets, 20124.2 The US Anti-Cancer Drug Market, 2013-2023 - Continued Leadership or Terminal Decline?4.3 The Japanese Anti-Cancer Drug Market, 2013-20234.4 The Leading Five Anti-Cancer Drug Markets in the EU (EU5), 2013-2023 - Serious Competitors to the US Market?4.5 Anti-Cancer Drug Markets in BRIC Countries, 2013-2023 - Awakening Sleeping Giants?4.5.1 Brazil, 2013-2023- BRIC's Smallest Market4.5.2 Russia, 2013-2023 - Rising Cancer Rates Drive Growth4.5.3 India, 2013-2023 - Lucrative Opportunity for Growth4.5.4 China, 2013-2023 - Can This Market Fulfil Vast Potential?5. Top 25 Anti-Cancer Drugs: Market Prospects, 2013-20235.1 Rituxan/MabThera (Roche) - The World's Leader5.1.1 Rituxan Sales, 20125.1.2 Competition Facing Rituxan - David vs. Goliath5.1.3 Rituxan Sales Forecast, 2013-20235.2 Herceptin (Roche)5.2.1 Herceptin Sales, 20125.2.2 Competition Facing Herceptin - A Tough Act to Follow5.2.3 Rituxan Sales Forecast, 2013-20235.3 Avastin (Roche) - Slowing Growth5.3.1 Avastin Sales, 20125.3.2 Competition Facing Avastin - Many Newer Options5.3.3 Avastin Sales Forecast, 2013-20235.4 Gleevec (Novartis)5.4.1 Gleevec Sales, 20125.4.2 Competition Facing Gleevec - Looming Generic Challengers5.4.3 Gleevec Sales Forecast, 2013-20235.5 Revlimid (Celgene) - Celgene's Main Revenue Generator5.5.1 Revlimid Sales, 20125.5.2 Competition Facing Revlimid - A Crowded Market5.5.3 Revlimid Sales Forecast, 2013-2023 - A Long-Term Leader?5.6 Alimta (Eli Lilly)5.6.1 Alimta Sales, 20125.6.2 Competition Facing Alimta - Strong Challengers Await5.6.3 Alimta Sales Forecast, 2013-2023 - Revenue Erosion Looming5.7 Velcade (Takeda/J&J)5.7.1 Velcade Sales, 20125.7.2 Competition Facing Velcade - A New Product to Worry About5.7.3 Velcade Sales Forecast, 2013-2023 - A Dependable Revenue Generator5.8 Gardasil (Merck & Co.) - One Vaccine to Dominate?5.8.1 Gardasil Sales, 20125.8.2 Competition Facing Gardasil - Only One Challenger That Matters5.8.3 Gardasil Sales Forecast, 2013-2023 - Merck's Revenue Generator5.9 Xeloda (Roche)5.9.1 Xeloda Sales, 20125.9.2 Competition Facing Xeloda - Is It Up To The Challenge?5.9.3 Xeloda Sales Forecast, 2013-20235.10 Tarceva (Roche)5.10.1Tarceva Sales, 20125.10.2 Competition Facing Tarceva - A Number of Other Options5.10.3 Tarceva Sales Forecast, 2013-2023 - An Excellent Return5.11 Sutent (Pfizer) - A Replacement for Gleevec5.11.1 Sutent Sales, 20125.11.2 Competition Facing Sutent5.11.3 Sutent Sales Forecast, 2013-2023 - Solid Sales for Several More Years5.12 Zoladex (AstraZeneca) - Prominent Hormone Therapy5.12.1 Zoladex Sales, 20125.12.2 Competition Facing Zoladex5.12.3 Zoladex Sales Forecast, 2013-20235.13 Sprycel (Bristol-Myers Squibb)5.13.1 Sprycel Sales, 2012 - Rapid Growth5.13.2 Competition Facing Sprycel5.13.3 Sprycel Sales Forecast, 2013-2023 - How Long Will the Growth Last?5.14 Nexavar (Bayer/Onyx)5.14.1 Nexavar Sales, 2012- Stalled Growth?5.14.2 Competition Facing Nexavar5.14.3 Nexavar Sales Forecast, 2013-2023 - More Years of Success5.15 Tasigna (Novartis)5.15.1 Tasigna Sales, 2012 - Blockbuster Revenue5.15.2 Competition Facing Tasigna5.15.3 Tasigna Sales Forecast, 2013-2023 - A Multi-Billion Dollar Product?5.16 Eloxatin (Sanofi)5.16.1 Eloxatin Sales, 20125.16.2 Competition Facing Eloxatin - Looming Patent Expiry5.16.3 Eloxatin Sales Forecast, 2013-20235.17 Temodar/Temodal (Merck & Co.)5.17.1 Temodar Sales, 20125.17.2 Competition Facing Temodar5.17.3 Temodar Sales Forecast, 2013-2023 - Generic Competition Awaits5.18 Vidaza (Celgene)5.18.1 Vidaza Sales, 20125.18.2 Competition Facing Vidaza - Generic Competitor a Matter of Time5.18.3 Vidaza Sales Forecast, 2013-20235.19 Afinitor (Novartis) - A Breast Cancer Breakthrough5.19.1 Afinitor Sales, 2012 - Another Success5.19.2 Competition Facing Afinitor5.19.3 Afinitor Sales Forecast, 2013-20235.20 Xgeva (Amgen)5.20.1 Xgeva Sales, 2012- Massive Growth in Sales5.20.2 Competition Facing Xgeva5.20.3 Xgeva Sales Forecast, 2013-2023 - Expectations Are High5.21 Taxotere (Sanofi)5.21.1 Taxotere Sales, 2012 - How Rapid a Revenue Erosion?5.21.2 Competition Facing Taxotere5.21.3 Taxotere Sales Forecast, 2013-20235.22 Yervoy (Bristol-Myers Squibb)5.22.1 Yervoy Sales, 2012 - Revenue Expansion Possible5.22.3 Competition Facing Yervoy5.22.3 Yervoy Sales Forecast, 2013-2023 - How Many Years of Growth Await?5.23 Erbitux (Bristol-Myers Squibb)5.23.1 Erbitux Sales, 20125.23.2 Competition Facing Erbitux5.23.3 Erbitux Sales Forecast, 2013-2023 - Gradual Drop in Revenues Expected5.24 Faslodex (AstraZeneca) - Zoladex's Counterpart5.24.1 Faslodex Sales, 2012 - Europe and Japan Lead the Way5.24.2 Competition Facing Faslodex5.24.3 Faslodex Sales Forecast, 2013-20235.25 Treanda (Teva Pharmaceuticals)5.25.1 Treanda Sales, 20125.25.2 Competition Facing Treanda5.25.3 Treanda Sales Forecast, 2013-2023 - Stalled Revenue Growth?6. Drugs Approved 2012-2013: Tomorrow's Blockbusters? 6.1 FDA-Approved Treatments in 20136.1.1 Kadcyla (Roche): A Potential Game-Changer6.1.1.1 Market Potential6.1.2 Pomalyst (Celgene)6.1.2.1 Market Potential: An Addition to a Crowded Market6.2 FDA-Approved Treatments in 2012: Rise of the Targeted Therapies6.2.1 Abraxane (Celgene)6.2.1.1 Market Potential: A Lower-Cost Alternative to Existing Treatments6.2.2 Afinitor (Novartis)6.2.2.1 Market Potential: More Indications, Greater Revenues?6.2.3 Bosulif (Pfizer): Pfizer's Answer to Novartis6.2.3.1 Market Potential6.2.4 Cometriq (Exelixis)6.2.4.1 Market Potential: Welcome Addition to an Open Market6.2.5 Erivedge (Roche): A Future Blockbuster?6.2.5.1 Market Potential6.2.6 Iclusig (Ariad Pharmaceuticals)6.2.6.1 Market Potential: A Capable Alternative to Gleevec6.2.7 Inlyta (Pfizer)6.2.7.1 Market Potential: Just Another Tyrosine Kinase Inhibitor?6.2.8 Krypolis (Onyx Pharmaceuticals)6.2.8.1 Market Potential: Stiff Competition May Blunt Growth6.2.9 Marqibo (Talon Therapeutics)6.2.9.1 Market Potential6.2.10 Perjeta (Roche)6.2.10.1 Market Potential6.2.11Stivarga (Bayer HealthCare Pharmaceuticals)6.2.11.1 Market Potential: Another Option for Patients6.2.12 Synribo (Teva Pharmaceuticals)6.2.12.1 Market Potential: A Potential Cash Cow6.2.13 Votrient (GlaxoSmithKline): GSK's Newest Entry6.2.13.1 Market Potential6.2.14 Xtandi (Medivation): Prostate Cancer's Newest Foe6.2.14.1 Market Potential6.2.15 Zaltrap (Sanofi):6.2.15.1 Market Potential: Sanofi's Newest Anti-Cancer Winner?7. Leading Companies for Cancer Treatments, 20137.1 Anti-Cancer Drug Market Dominated by Six Companies7.2 Roche - The World's Foremost Oncology Company7.2.1 Oncology Pipeline - Investment in the Future7.2.2 Future Directions in Cancer Treatment7.3 Novartis - Tomorrow's Leader?7.3.1 Oncology R&D Pipeline - What's the Po迷你倉新蒲崗ential?7.3.2 Future Directions in Cancer Treatment7.4 Celgene - Pressing Need to Diversify?7.4.1 Oncology Pipeline - Safeguarding Celgene's Future7.4.2 Future Directions in Cancer Treatment7.5 AstraZeneca - A Well-Balanced Portfolio7.5.1 Oncology Pipeline - Showing Promise7.5.2 Future Directions in Cancer Treatment7.6 Eli Lilly - How Strong is its Contribution to the Market?7.6.1 Oncology Pipeline - What Potential Exists?7.6.2 Future Directions in Cancer Treatment7.7 Merck & Co. - Prominent in Vaccines7.7.1 Oncology Pipeline - Greater Focus on Oncology7.7.2 Future Directions in Cancer Treatment8. R&D Pipelines for Cancer Treatment8.1 Bladder Cancer Drugs Under Development8.1.1 Profile: EOquin (Allergan)8.2 Brain Cancer Drugs Under Development8.2.1 Profile: Rindopepimut (Celldex Therapeutics)8.3 Breast Cancer Drugs Under Development8.3.1 Afatinib (Boehringer Ingelheim)8.4 Cervical Cancer Drugs Under Development8.4.1 Profile: V503 (Merck & Co.)8.5 Colorectal Cancer Drugs Under Development8.5.1 Aptocine (Light Sciences Oncology)8.6 Kidney Cancer Drugs Under Development8.6.1 Rencarex (Wilex)8.7 Leukaemia Drugs Under Development8.7.1 Obinutuzumab (Roche)8.8 Liver Cancer Drugs Under Development8.8.1 Brivanib (Bristol-Myers Squibb)8.9 Lung Cancer Drugs Under Development8.9.1 BIBF 1120 (Boehringer Ingelheim)8.10 Lymphoma Drugs Under Development8.10.1 Inotuzumab Ozogamicin (Pfizer)8.11 Multiple Myeloma Drugs Under Development8.11.1 LBH589 (Novartis)8.12 Ovarian Cancer Drugs Under Development8.12.1 AMG 386 (Amgen)8.13 Pancreatic Cancer Drugs Under Development8.13.1 AMG 479 (Amgen)8.14 Prostate Cancer Drugs Under Development8.14.1 MDV-3100 (Astellas Pharma US/Medivation)8.15 Sarcoma Drugs Under Development8.15.1 Mifamurtide (Millennium Pharmaceuticals)8.16 Skin Cancer Drugs Under Development8.16.1 Allovectin (Vical)8.17 Stomach Cancer Drugs Under Development8.17.1 Ramucirumab (Eli Lilly/ImClone Systems)8.18 Other Cancer Drugs Under Development8.18.1 Lenvatinib (Eisai)9. SWOT and STEP Analyses, 20139.1 Strengths of the Industry and Market9.1.1 High Profile of Cancer9.1.2 Off-Label Prescriptions Common9.1.3 Drug Development Incentives9.2 Weaknesses of the Industry and Market9.2.1 Tumour Resistance9.2.2 Pricing-Out the Developing World?9.3 Opportunities for the Industry and Market9.3.1 Rising Incidence of Cancer9.3.1.1 Ageing Populations9.3.1.2 Smoking9.3.1.3 Obesity9.3.1.4 The Developing World9.3.2 Personalised Medicine9.3.3 Live Licensing9.3.4 Convenient Drugs9.4 Threats Facing the Industry and Market9.4.1 The Cost-Effectiveness Debate9.4.2 Governments: Leading Payers for Drugs9.4.3 Efficacy, Toxicity and Alternative Treatments9.5 Biosimilars and Generics: Opportunity or Threat?9.6 Personalised Medicine9.6.1 Cancer Heterogeneity9.6.2 Pharmacogenomics9.6.3 Genome Screening9.6.4 Biomarkers and Diagnostics9.6.5 Theranostics10. Research Interviews10.1 Interview with Dr Sidong Huang, Assistant Professor of Biochemistry at McGill University10.1.1 On His Research Interests and their Utility in Anti-Cancer Drug Development10.1.2 On the Evaluation of New Targets for Anti-Cancer Drugs10.1.3 On Drug Resistance and Targeted Therapies10.1.4 On the Future of Traditional Chemotherapy10.1.5 On Future Developments in the Anti-Cancer Field10.2 Interview with Dr Neil Butt, Director, Antitope Ltd.10.2.1 On Immunogenicity in Therapeutic Proteins10.2.2 On Antitope's Technologies to Assess and Reduce Immunogenicity10.2.3 On an Alternative Way of Reducing Immunogenicity10.2.4 On Biosimilars10.2.5 On Future Developments in this Field10.3 Interview with Dr Kent C. Osborne, Baylor College of Medicine10.3.1 On Challenges in Developing Anti-Cancer Therapies10.3.2 On Major Areas of Focus10.3.3 On Cancer Vaccines10.3.4 On Areas with Potential for Increased Revenue Generation10.3.5 On the R&D Pipeline10.3.6 On Difficulties Conducting Clinical Trials11. Conclusions11.1 Top 25 Drugs in the World Cancer Treatment Market11.2 Immunotherapies - The Driving Force11.2.1 Biosimilars Have Potential in Emerging Markets11.3 The US- the Largest Anti-Cancer Drug Market11.4 India and China Will be the Fastest-Growing National Markets11.5 Personalised Medicine - the Future of Cancer Therapy11.6 Anti-Cancer Drug Pipeline Remains Strong11.7 Concluding RemarksList of TablesTable 2.1 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2013Table 2.2 Cancer-Treating Agents: Immunotherapies, Targeted Therapies and Differentiating Agents, 2013Table 3.1 Global Anti-Cancer Market Sales ($bn), Annual Growth Rates (%) and Market Shares (%) by Segment, 2011 and 2012Table 3.2 Global Anti-Cancer Market Forecast ($bn), 2012-2013Table 3.3 Global Anti-Cancer Drug Market: Revenue Forecasts by Category ($bn), 2012-2023Table 3.4 Global Anti-Cancer Market: Drivers and Restraints, 2013Table 3.5 Global Immunotherapies Market ($bn), 2012Table 3.6 Immunotherapy Market Forecast ($bn), 2012-2023Table 3.7 Immunotherapy Market: Drivers and Restraints, 2013Table 3.8 Global Targeted Therapies Market ($bn), 2012Table 3.9 Targeted Therapies Market Forecast ($bn), 2012-2023Table 3.10 Targeted Therapies Market: Drivers and Restraints, 2013Table 3.11Hormone Therapy Market Forecast ($bn), 2012-2023Table 3.12 Hormone Therapy Market: Drivers and Restraints, 2013Table 3.13 Global Chemotherapies Market ($bn), 2012Table 3.14 Chemotherapy Market Forecast ($bn), 2012-2023Table 3.15 Chemotherapy Market: Drivers and Restraints, 2013Table 4.1 Anti-Cancer Drug Market by Leading Country ($bn), 2012, 2017 and 2023Table 4.2 Developed Markets: Drivers and Restraints, 2013Table 4.3 Emerging Markets: Drivers and Restraints, 2013Table 4.4 Global Anti-Cancer Drug Market: Forecasts by Leading Country ($bn), 2012-2023Table 4.5 US Anti-Cancer Drug Market Forecast ($bn), 2012-2023Table 4.6 Japanese Anti-Cancer Drug Market Forecast ($bn), 2012-2023Table 4.7 The Leading 5 EU Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023Table 4.8 BRIC Countries: Anti-Cancer Drug Markets: Forecasts ($bn), 2012-2023Table 5.1 Top 25 Anti-Cancer Drugs: Sales ($bn) and Market Shares (%), 2012Table 5.2 Top 5 Companies in the Anti-Cancer Drugs Market: Sales ($bn) and Market Shares (%), 2012Table 5.3 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023Table 5.4 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)Table 5.5 Top 25 Anti-Cancer Drugs: Sales Forecasts ($bn), 2012-2023 (Contd.)Table 5.6 Rituxan Sales Forecast ($bn), 2012-2023Table 5.7 Rituxan: Sales Drivers and Restraints, 2013Table 5.8 Herceptin Sales Forecast ($bn), 2012-2023Table 5.9 Herceptin: Sales Drivers and Restraints, 2013Table 5.10 Avastin Sales Forecast ($bn), 2012-2023Table 5.11 Avastin: Sales Drivers and Restraints, 2013Table 5.12 Gleevec Sales Forecast ($bn), 2012-2023Table 5.13 Gleevec: Sales Drivers and Restraints, 2013Table 5.14 Revlimid Sales Forecast ($bn), 2012-2023Table 5.15 Revlimid: Sales Drivers and Restraints, 2013Table 5.16 Alimta Sales Forecast ($bn), 2012-2023Table 5.17 Alimta: Sales Drivers and Restraints, 2013Table 5.18 Velcade Sales Forecast ($bn), 2012-2023Table 5.19 Velcade: Sales Drivers and Restraints, 2013Table 5.20 Gardasil Sales Forecast ($bn), 2012-2023Table 5.21 Gardasil: Sales Drivers and Restraints, 2013Table 5.22 Xeloda Sales Forecast ($bn), 2012-2023Table 5.23 Xeloda: Sales Drivers and Restraints, 2013Table 5.24 Tarceva Sales Forecast ($bn), 2012-2023Table 5.25 Tarceva: Sales Drivers and Restraints, 2013Table 5.26 Sutent Sales Forecast ($bn), 2012-2023Table 5.27 Sutent: Sales Drivers and Restraints, 2013Table 5.28 Zoladex Sales Forecast ($bn), 2012-2023Table 5.29 Zoladex: Sales Drivers and Restraints, 2013Table 5.30 Sprycel Sales Forecast ($bn), 2012-2023Table 5.31 Sprycel: Sales Drivers and Restraints, 2013Table 5.32 Nexavar Sales Forecast ($bn), 2012-2023Table 5.33 Nexavar: Sales Drivers and Restraints, 2013Table 5.34 Tasigna Sales Forecast ($bn), 2012-2023Table 5.35 Tasigna Sales Drivers and Restraints, 2013Table 5.36 Eloxatin Sales Forecast ($bn), 2012-2023Table 5.37 Eloxatin: Sales Drivers and Restraints, 2013Table 5.38 Temodar Sales Forecast ($bn), 2012-2023Table 5.39 Temodar Sales Drivers and Restraints, 2013Table 5.40 Vidaza Sales Forecast ($bn), 2012-2023Table 5.41 Vidaza Sales Drivers and Restraints, 2013Table 5.42 Afinitor Sales Forecast ($bn), 2012-2023Table 5.43 Afinitor Drivers and Restraints, 2013Table 5.44 Xgeva Sales Forecast ($bn), 2012-2023Table 5.45 Xgeva Drivers and Restraints, 2013Table 5.46 Taxotere Sales Forecast ($bn), 2012-2023Table 5.47 Taxotere: Sales Drivers and Restraints, 2013Table 5.48 Yervoy Sales Forecast ($bn), 2012-2023Table 5.49 Yervoy: Sales Drivers and Restraints, 2013Table 5.50 Erbitux Sales Forecast ($bn), 2012-2023Table 5.51 Erbitux: Sales Drivers and Restraints, 2013Table 5.52 Faslodex Sales Forecast ($bn), 2012-2023Table 5.53 Faslodex: Sales Drivers and Restraints, 2013Table 5.54 Treanda Sales Forecast ($bn), 2012-2023Table 5.55 Treanda: Sales Drivers and Restraints, 2013Table 7.1 Anti-Cancer Drug Sales ($bn) and Market Shares (%) by Leading Company, 2012Table 7.2 Roche Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.3 Selected Drugs from Roche Oncology Pipeline, 2012Table 7.4 Novartis Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.5 Novartis Oncology Pipeline, 2012Table 7.6 Celgene Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.7 Celgene Oncology Pipeline, 2012Table 7.8 AstraZeneca Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.9 Selected Drugs from AstraZeneca Oncology Pipeline, 2012Table 7.10 Eli Lilly Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.11 Selected Drugs from Eli Lilly Oncology Pipeline, 2012Table 7.12 Merck & Co. Anti-Cancer Drugs: Sales ($bn), 2011-2012Table 7.13 Merck & Co. Oncology Pipeline, 2012Table 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012Table 8.2 Bladder Cancer: Some Late Stage Drugs Under Development, 2012Table 8.3 Brain Cancer: Some Late Stage Drugs Under Development, 2012Table 8.4 Breast Cancer: Some Late Stage Drugs Under Development, 2012Table 8.5 Cervical Cancer: Some Late Stage Drugs Under Development, 2012Table 8.6 Colorectal Cancer: Some Late Stage Drugs Under Development, 2012Table 8.7 Kidney Cancer: Some Late Stage Drugs Under Development, 2012Table 8.8 Leukaemia: Some Late Stage Drugs Under Development, 2012Table 8.9 Liver Cancer: Some Late Stage Drugs Under Development, 2012Table 8.10 Lung Cancer: Some Late Stage Drugs Under Development, 2012Table 8.11 Lymphoma: Some Late Stage Drugs Under Development, 2012Table 8.12 Multiple Myeloma: Late Stage Drug Under Development, 2012Table 8.13 Ovarian Cancer: Some Late Stage Drugs Under Development, 2012Table 8.14 Pancreatic Cancer: Some Late Stage Drugs Under Development, 2012Table 8.15 Prostate Cancer: Some Late Stage Drugs Under Development, 2012Table 8.16 Sarcoma: Some Late Stage Drugs Under Development, 2012Table 8.17 Skin Cancer: Some Late Stage Drugs Under Development, 2012Table 8.18 Stomach Cancer: Some Late Stage Drugs Under Development, 2012Table 8.19 Other Cancers: Some Late Stage Drugs Under Development, 2012Table 9.1 SWOT Analysis of the Anti-Cancer Drugs Market, 2013Table 9.2 STEP Analysis of the Anti-Cancer Drug Market, 2013List of FiguresFigure 3.1 World Anti-Cancer Market Shares (%) by Segment, 2012Figure 3.2 Global Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 3.3 Global Anti-Cancer Market Shares (%) by Category, 2013Figure 3.4 Global Anti-Cancer Market Shares (%) by Category, 2023Figure 3.5 Immunotherapy Market Forecast ($bn), 2012-2023Figure 3.6 Targeted Therapies Market Forecast ($bn), 2012-2023Figure 3.7 Hormone Therapy Market Forecast ($bn), 2012-2023Figure 3.8 Chemotherapy Market Forecast ($bn), 2012-2023Figure 4.1 Anti-Cancer Drug Market Shares (%) by Leading Country, 2012Figure 4.2 Anti-Cancer Drug Market Shares (%) by Leading Country, 2017Figure 4.3 Anti-Cancer Drug Market Shares (%) by Leading Country, 2023Figure 4.4 US Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.5 Japanese Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.6 Leading 5 EU Anti-Cancer Drug Market Forecasts ($bn), 2012-2023Figure 4.7 Brazilian Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.8 Russian Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.9 Indian Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 4.10 Chinese Anti-Cancer Drug Market Forecast ($bn), 2012-2023Figure 5.1 Global Market Shares (%) of the Main Companies in the Anti-Cancer Drugs Market, 2012Figure 5.2 Rituxan Sales Forecast ($bn), 2012-2023Figure 5.3 Herceptin Sales Forecast ($bn), 2012-2023Figure 5.4 Avastin Sales Forecast ($bn), 2012-2023Figure 5.5 Gleevec Sales Forecast ($bn), 2012-2023Figure 5.6 Revlimid Sales Forecast ($bn), 2012-2023Figure 5.7 Alimta Sales Forecast ($bn), 2012-2023Figure 5.8 Velcade Sales Forecast ($bn), 2012-2023Figure 5.9 Gardasil Sales Forecast ($bn), 2012-2023Figure 5.10 Xeloda Sales Forecast ($bn), 2012-2023Figure 5.11 Tarceva Sales Forecast ($bn), 2012-2023Figure 5.12 Sutent Sales Forecast ($bn), 2012-2023Figure 5.13 Zoladex Sales Forecast ($bn), 2012-2023Figure 5.14 Sprycel Sales Forecast ($bn), 2012-2023Figure 5.15 Nexavar Sales Forecast ($bn), 2012-2023Figure 5.16 Tasigna Sales Forecast ($bn), 2012-2023Figure 5.17 Eloxatin Sales Forecast ($bn), 2012-2023Figure 5.18 Temodar Sales Forecast ($bn), 2012-2023Figure 5.19 Vidaza Sales Forecast ($bn), 2012-2023Figure 5.20 Afinitor Sales Forecast ($bn), 2012-2023Figure 5.21 Xgeva Sales Forecast ($bn), 2012-2023Figure 5.22 Taxotere Sales Forecast ($bn), 2012-2023Figure 5.23 Yervoy Sales Forecast ($bn), 2012-2023Figure 5.24 Erbitux Sales Forecast ($bn), 2012-2023Figure 5.25 Faslodex Sales Forecast ($bn), 2012-2023Figure 5.26 Treanda Sales Forecast ($bn), 2012-2023Figure 7.1 Anti-Cancer Drug Market Shares (%) by Leading Company, 2012Figure 8.1 Cancer Medicines in Testing: Numbers by Therapeutic Area, 2012Figure 11.1 Top 25 Anti-Cancer Drugs: Sales ($bn), 2012Companies ListedAbbott LaboratoriesAdvaxisAeterna ZentarisAgenusAlgetaAllerganAmbit BiosciencesAmerican Cancer SocietyAmgenAntitopeAPP PharmaceuticalsAriad PharmaceuticalsArQuleArray BioPharmaAstellas PharmaAstraZenecaAVEO PharmaceuticalsBayer HealthCareBaylor College of MedicineBioCancell TherapeuticsBiogen IdecBioniche Life SciencesBioVEXBiPar SciencesBoehringer IngelheimBioconBristol-Myers Squibb (BMS)Cancer AdvancesCelgeneCelldex TherapeuticsChugaiCiplaCyclacel PharmaceuticalsDaiichi SankyoDakoDan L. Duncan Cancer CenterDendreonDr. Reddy's LaboratoriesEisaiEleison PharmaceuticalsEli LillyEMD SeronoEndo PharmaceuticalsEuropean Medicines Agency (EMA)ExelixisFood and Drug Administration (US FDA)Galena BiopharmaGE HealthcareGenentechGenMabGentaGenzymeGlaxoSmithKline (GSK)HospiraImClone SystemsInovio PharmaceuticalsInternational Cancer Genome ConsortiumJanssen-CilagJohnson & Johnson (J&J)Keryx BiopharmaceuticalsLester and Sue Smith Breast Center, Baylor College of MedicineLpathMarshall EdwardsMcGill UniversityMedImmuneMedivationMenariniMerck & Co.Merck SeronoMillennium PharmaceuticalsMylanNational Cancer InstituteNational Health Service (UK)National Institute for Health and Clinical Excellence (NICE, UK)Nektar TherapeuticsNovartisOncoGenex PharmaceuticalsOnconova TherapeuticsOnyx PharmaceuticalsOSI PharmaceuticalsOtsukaOxford UniversityPfizerPharmaceutical Research and Manufacturers of America (PhRMA)PlexxikonProgen PharmaceuticalsProteolixPuma BiotechnologyRadientRegeneronRocheSandozSanofiSeattle GeneticsSkin Cancer FoundationSpectrum PharmaceuticalsSyndax PharmaceuticalsTactic PharmaTalon TherapeuticsTaiho Pharma USATakedaTenX BiopharmaTeva Pharmaceutical IndustriesTransgeneUCBUnited TherapeuticsVaccine CompanyWellstat BiologicsWilexWorld Health Organization (WHO)ZIOPHARM OncologyTo order this report: Leading Anti-Cancer Drugs and Associated Market 2013-2023 .reportlinker.com/p0819459/Leading-Anti-Cancer-Drugs-and-Associated-Market-2013-2023.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication__________________________Contact Clare: clare@reportlinker.com US: (339)-368-6001Intl: +1 339-368-6001ReportlinkerWeb site: .reportlinker.com/迷你倉出租